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ABSTRACT 
It is well known that patients with rheumatoid arthritis (RA) are at increased risk of developing or dying 
from cardiovascular disease (CVD). There are several important questions remaining regarding the 
association between RA and specific CVDs. In this work, we have identified gaps in the existing 
knowledge and translated them into the objectives of the four sub-studies included in this thesis, which 
all focus on clinical aspects of CVD in RA.  
Several studies have assessed potential risk factors for CVD overall in RA, whereas no previous study has 
investigated the impact of RA-related factors on the risk of clinically significant acute coronary 
syndrome (ACS) in contemporary RA-patients. Existing results are thereby difficult to extrapolate into 
clinical praxis. Using a nested case-control design, we therefore aimed in Study I to investigate risk 
factors for ACS in new-onset RA. We found that laboratory measures of high inflammatory activity, 
clinical markers of high disease activity as well as poorer perceived health and a high number of sick 
days already during the first year following RA-onset were associated with an increased risk of ACS in 
RA. Seropositivity for the autoantibody rheumatoid factor (RF) was not associated with ACS, whereas 
antibodies towards citrullinated peptides (ACPAs) and in particular high positive levels of ACPAs was 
associated with an increased risk of ACS. 
Thus, the increased risk of ACS in patients with RA seems to be, at least partly, driven by inflammatory 
activity. Inflammation is known to affect the extent and composition of atherosclerosis, why the clinical 
phenotype of ACS in RA might differ compared with non-RA patients. However, little is known about 
the actual clinical phenotype, its treatment, follow-up care and outcomes of ACS in RA. For this reason, 
we investigated clinical ACS characteristics, short- and long-term outcomes and the usage of gold 
standard secondary preventive drugs in 1,135 RA-patients with ACS compared to 3,184 non-RA patients 
with ACS in Studies II and III. Our results indicated that patients with RA suffer from more severe ACS 
compared with non-RA patients. Furthermore, patients with RA also suffer from an increased risk of 
developing recurrent events or dying after the ACS. Usage of secondary preventive drugs was not 
substantially different in patients with RA compared with non-RA patients, and did not seem to explain 
the impaired prognosis following ACS.  
In the fourth and final study, we focused on assessing the relative risk (RR) of heart failure (HF) in RA, 
which, despite the known involvement of inflammation in the pathogenesis of HF, has only been 
assessed in a few studies. In Study IV, we estimated the relative risk (RR) of HF in RA both in the 
presence and absence of ischemic heart disease (IHD) in patients with new-onset RA and patients with 
established RA compared with non-RA patients. We also investigated the impact of RA-related 
inflammation on the risk of HF in patients with new-onset RA. We found that the risk of both ischemic 
and nonischemic HF was increased in RA. The risk increase, in particular for nonischemic HF, 
developed early after RA-onset and was associated with high inflammatory activity.  
The results of the four studies emphasize the importance of early disease control in RA, suggest that RA 
comorbidity should be acknowledged when risk stratifying ACS patients and also point out the 
importance of observing and investigating clinical signs of HF in patients with RA.   
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1 INTRODUCTION  
Rheumatoid arthritis (RA) is, according to the World Health Organization, one of the 
musculoskeletal conditions with the greatest impact on society.2RA-onset typically 
occurs in middle-aged individuals in their most productive years. It is a chronic 
condition, often associated with pain and functional impairment, leading to 
substantial disability throughout life. In addition to the disability caused by the RA 
itself, patients with RA are also at increased risk of developing several other comorbid 
conditions3 adding to the already existing disease-related morbidity. Cardiovascular 
disease (CVD) is the most common comorbidity in RA.4 The increased risk of CVD 
was first observed several decades ago, and later studies have reported risk increases of 
magnitudes similar to what is observed in diabetes mellitus (DM) type 2.5, 6 Patients 
with RA are at increased risk of most subtypes of CVDs, which accounts for a majority 
of the excess mortality and morbidity seen in RA.7 Importantly, the presence of 
traditional CV risk factors cannot fully explain the increased risk of CVD in RA, which 
has led to attempts to identify other risk factors involved in the pathogenesis of CVD 
in RA. Parallel to the increasing number of reports on the association between RA and 
CVD, the knowledge of the pathophysiology of specific CVDs, and in particular 
atherosclerosis, has progressed remarkably. The involvement of inflammatory activity 
in the development of atherosclerosis has been established and it has been 
demonstrated that inflammation affects the extent and composition of atherosclerotic 
lesions. Recently, an association between inflammation and heart failure (HF) has also 
been established. The RA-related inflammation might therefor be involved in the 
development of CVD in RA, which potentially also affects the characteristics and 
outcomes of CVD in RA.  
Needless to say, studying the association between RA and CVD can have multiple 
approaches and perspectives, making it a difficult but primarily an interesting and 
rewarding task. All four studies included in this thesis use epidemiological methods to 
study the risk of, risk factors for, clinical characteristics of and outcomes following 
acute coronary syndrome (ACS) and/or HF. Apart from elucidating the specific 
associations studied aiming to find ways to identify, treat or prevent CVD in patients 
with RA in clinical practice, the results may hopefully also be useful for understanding 
CV pathophysiology.  
Undoubtedly, trying to understand the aetiology of associations or diseases is a 
complicated task. Repeated investigations and translational research, combining 
several different research fields, is often required in order to confirm a hypothesis. The 
aim of this thesis is to highlight a few well-defined areas of the field, which can 
hopefully contribute a few of many pieces to the jigsaw puzzle.  
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2 BACKGROUND 
2.1 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a chronic inflammatory disease with predominant 
musculoskeletal manifestations. The key symptoms of RA are local inflammation of 
joints, tendons and bursae8, 9 and systemic inflammation leading to manifestations 
such as fatigue. RA is divided into two subgroups based on the presence of 
autoantibodies, including rheumatoid factor (RF) and autoantibodies against 
citrullinated peptides (ACPA).10  
2.1.1 Epidemiology 
RA has a reported global prevalence of 0.24%, and is ranked high among conditions 
contributing to global disability.11 In incidence and prevalence studies, the occurrence 
of RA typically varies between countries, ethnicities and racial groups.12 The reported 
prevalence of 0.5-1% in northern Europe and North American13 is higher compared 
with, for example, southern European countries and low-income countries, where the 
incidence and prevalence is reported to be significantly lower.14 Despite some 
differences in RA-definition, methodological approach and the apparent difficulties in 
estimating disease occurrence in low-income countries, these observed variations are 
likely to be partly true. Naturally, this observation has led to assessments of the effects 
of potential environmental factors, such as diet, and genetic factors on the risk of RA.15 
In a large Swedish register-based study, approximately 60,000 individuals with RA 
were identified in 2008, corresponding to a prevalence of 0.77%.16 The nationwide 
incidence in Sweden is approximately 40 per 100,000, twice as common in women and 
increases with age.17 
2.1.2 Risk factors and pathogenesis  
Several genetic and environmental risk factors for RA have been identified to date. A 
family history of RA is a strong risk factor for developing RA with two to six times 
higher prevalence in individuals with first-degree relatives with RA.18 The heritability 
is stronger for seropositive compared to seronegative disease.19, 20 Genome-wide 
association studies have identified over a hundred genetic risk alleles that are 
associated with risk of RA.21 A majority of these alleles are located within the human 
leukocyte antigen (HLA) complex, a region on chromosome 6 with certain genes 
known to play a crucial role in the susceptibility and pathogenesis of several 
autoimmune diseases.22, 23 In particular, there are disease-associated alleles (termed 
shared epitope [SE]) in the HLA-DRB1 gene that have been associated with an 
increased risk of RA.24 Cigarette smoking seems to be the most important 
environmental risk factor for RA 25-28 and is in particular associated with RF- and CCP-
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positive RA29 in the presence of the SE-alleles,30 indicating an epigenetic contribution 
to the RA pathogenesis via gene-environment interactions.30-32 Low socioeconomic 
status,33 low educational level,34 physical workload35 and hormonal factors 36-39and 
work-related exposure to silica-dust40 and textile dust41 have also been associated with 
an increased risk of RA. Alcohol intake 42, 43 and a diet high in fish oil 44 have been 
proposed to decrease the risk of developing RA.  
Despite the large amount of research in the field, the specific pathogenesis is not yet 
completely understood. It is presumed that the interaction between environmental 
factors, such as smoking, and genetic factors, such as the SE alleles,45 triggers 
epigenetic modifications, i.e. citrullination and subsequent immunological response 
leading to inflammation and hence corresponding symptoms and clinical signs. Many 
immunological cells, pathways and mediators have been identified as central in the 
pathogenesis of RA.8, 46 Briefly, antigen presenting cells are triggered to activate CD4+ 
T cells. The T-cells differentiate into specific subtypes of T-cells, which in turn activate 
B-cells and stimulate macrophages and fibroblasts to secrete proinflammatory 
mediators, such as tumour necrosis factor α (TNF-α) and different interleukins.47 
Certain B-cells produce ACPAs, which can be detected several years prior to RA-onset 
and are a strong predictors for disease.48, 49 The autoantibodies can bind various 
citrullinated self-proteins8 in different tissues which, except for the potential role in 
the pathogenesis of RA, has also been suggested as being involved in the pathogenesis 
of other diseases.50 Additionally, ACPAs are themselves pathogenic by activating 
macrophages and immune complex formation, triggering the immune system. The 
key clinical feature of joint swelling in RA is a consequence of synovial membrane 
inflammation due to the immune activation. The inflammatory milieu within the 
synovial compartment consists of a variety of immune cells and complex cytokine and 
chemokine networks. Enhanced chondrocyte metabolism leads to destruction of the 
cartilage. Aggravation of the inflammation can trigger osteoclast generation and 
subsequent bony erosions.8, 47 
2.1.3 Symptoms, diagnosis and classification 
The disease onset of RA can be acute or insidious and, as already described, the 
common presenting symptoms are tender and swollen joints, and symptoms of 
systemic inflammation, such as fatigue. The joints most frequently involved are the 
wrists, metocarpophalangeal (MCP) and proximal interphalangeal (PIP) joints. 
Laboratory tests typically shows elevated concentrations of C-reactive protein (CRP) 
and erythrocyte sedimentation rate (ESR).8, 47 There are no specific diagnostic criteria 
for RA, but, after eliminating several potential differential diagnoses, the diagnosis can 
be aided by classification criteria developed, and most recently updated in 2010, by the 
American College of Rheumatology (ACR) and the European League against 
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Rheumatism (EULAR).51 The 2010 ACR/EULAR criteria aim to detect patients with RA 
early to identify those who would benefit from early disease-modifying therapy. Based 
on the number of the affected joints, presence of autoantibodies (RF and ACPAs), 
acute-phase reactants (CRP and ESR) and duration of symptoms, a score between 0 
and 10 is yielded, where a score above 6 indicates definite RA (Figure 2.1). Patients not 
fulfilling the 2010 ACR/EULAR criteria, but with erosive disease (defined as a cortical 
break in at least three separate joints) are also classified as RA according to a more 
recent update.52 Importantly, the classification system also serves as a tool for 
identifying subgroups of RA patients, based on the presence or absence of RF and/or 
ACPAs. RA is, however, a heterogeneous disease with variability in clinical 
presentation and treatment response, which is why there are probably even further 
disease subgroups.53 Clinically, seropositive and seronegative RA (based on RF/ACPA 
status) are typically recognized as two distinct entities. Seropositive RA is associated 
with a more severe clinical prognosis.51, 54 
JOINT DISTRIBUTION (TENDER AND/OR SWOLLEN JOINTS) 
1 large joint 0 
2-10 large joints 1 
1–3 small‡ joints 2 
4–10 small‡ joints 3 
>10 joints (at least 1 small) 5 
SEROLOGY 
Negative RF AND negative ACPA 0 
Low positive RF OR low positive ACPA 2 
High positive RF OR high positive ACPA 3 
SYMPTOM DURATION 
< 6 Weeks 0 
≥ 6 Weeks 1 
ACUTE PHASE REACTANTS  
Normal CRP AND normal ESR 0 
Abnormal CRP OR abnormal ESR 1 
‡Small joints = Metocarpophalangeal joints, Proximal interphalangeal joints, 
Metotarsophalangeal joints and Radiocarpal joints 
RF, rheumatoid factor; ACPA, antibodies towards citrullinated peptides; CRP, c-
reactive protein; ESR, erythrocyte sedimentation rate  
Figure 2.1. The 2010 EULAR/ACS Classification criteria. ≥6 points indicates definite 
RA. (0-5) 
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2.1.4 Disease assessment and treatment 
Measurements of disease activity is important in the clinical evaluation of RA as well 
as in the research setting, and is typically evaluated using one of several existing 
composite measurements including clinical and laboratory parameters.55 The most 
commonly used measurement, the 28 joint count disease activity score (DAS28), was 
developed for this purpose, and is based on an algorithm including the tender and 
swollen joint count (of 28) assessed by the physician, ESR (or CRP) and general health 
(GH), i.e. assessed on a VAS scale. According to the DAS28, disease activity is 
classified into low, moderate or high.56High disease activity is related to impaired 
functional capacity and the progression of joint damage.57 Based on DAS28, there are 
also remission criteria, used to evaluate treatment targets.58 The health assessment 
questionnaire disability index (HAQ DI) is the most commonly used instrument used 
to assess physical functioning in patients with RA.59  
There are several efficacious drugs available for the treatment of RA. The overarching 
principles in the EULAR recommendations for the management of RA (updated 2016) 
include i) that a rheumatologist should be responsible for the treatment, ii) that the 
treatment should be chosen based on disease activity and other patient factors such as 
comorbidities, and iii) that treatment decision-making should be shared between the 
rheumatologist and the patient.60 The two major classes of disease-modifying anti-
rheumatic drugs (DMARDs) used to target the inflammatory activity are synthetics 
and biologics. Synthetic DMARDs are further divided into conventional or targeted 
synthetic DMARDs.61 Non-steroidal anti-inflammatory drugs (NSAIDs) are used to 
relieve symptoms, but do not have any effect on joint damage and are hence not 
disease-modifying.62 Treatment with glucocorticoids is also used, especially in early 
disease to relieve symptoms before the DMARD of choice has had any effect. 
According to the EULAR guidelines, DMARD treatment should be initiated in direct 
relation to the diagnosis. In the absence of contraindications, methotrexate (MTX), 
often in combination with glucocorticoids, is the first treatment choice. The aim of 
treatment is reaching sustained remission or low disease activity, and evaluation 
should be undertaken frequently. If there is no improvement after three months of 
treatment, changing to another type of DMARD should be considered. Which type of 
DMARD that is used depends on the presence of prognostic factors such as 
autoantibodies should be considered. Biological DMARDs are often used in patients 
with seropositive RA or high disease activity where monotherapy with MTX has failed. 
Different combination therapies exist depending on subsequent evaluations and 
treatment response. When the treatment target is reached, the aim is to sustain it over 
time and thereafter consider tapering off the drugs.60, 63  
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2.1.5 Morbidity and mortality  
Patients with RA suffer from impaired quality of life64 as a consequence of the 
functional status related partly to RA, but importantly also influenced by the several 
comorbid conditions occurring more frequently in RA-subjects compared to non-RA 
subjects.65 Patients with RA suffer from increased mortality risk 66 and have a shorter 
life expectancy compared with the general population.67 Despite the observed 
decreased mortality rates in RA over recent decades, mortality is still significantly 
increased compared with the general population.68 The most common comorbid 
condition is cardiovascular disease (CVD), which contributes to a majority of both 
excess morbidity and mortality in RA.4, 7 RA is also associated with infectious diseases, 
diabetes mellitus (DM)69, renal diseases70, certain malignancies71-74 and depression.65, 
75, 76 
 
2.2 CARDIOVASCULAR DISEASE  
CVD is a broad disease group affecting blood vessels and/or the heart, and is the 
leading cause of death globally.77 A majority of the various subtypes of CVD share 
some pathophysiological mechanisms and clinical features, but they also have their 
own unique hallmarks, making it important to distinguish between them. This thesis 
include studies of the association between RA and acute coronary syndrome (ACS) 
and heart failure (HF), which is why these conditions are described in detail in this 
section.  
2.2.1 Ischemic heart disease 
Ischemic heart disease is a consequence of coronary artery disease (CAD), which is 
characterized by atherosclerosis of the coronary arteries. IHD can be asymptomatic or 
symptomatic and present as chronic stable angina or in acute onset as acute coronary 
syndrome (ACS). ACS includes the diagnoses unstable angina pectoris (UA) and 
myocardial infarction (MI). The aetiology of ACS is not always CAD, but can also be 
coronary spasm.78 
2.2.1.1 Traditional risk factors 
Identification of risk factors for CAD was initiated in 1948 in the Framingham heart 
study79 and subsequently many studies have replicated and extended these results. 
The traditional and currently well-known risk factors are divided into non-modifiable 
and modifiable or life-style related. Non-modifiable risk factors include age, male sex 
and hereditary factors. Major modifiable risk factors include hypertension, DM, 
smoking, physical inactivity, increased LDL-C and decreased HDL-L.80  
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2.2.1.2 Atherosclerosis and novel risk factors 
Atherosclerosis was previously considered a lipid storage disease, but the knowledge 
of the involvement of inflammation has progressed rapidly during the last decades. In 
fact, inflammatory activity is involved in all steps of the complex atherogenic 
pathway,81-83which shares similarities with the pathophysiological mechanisms in 
RA.84The development of atherosclerosis is initiated by endothelial dysfunction, which 
can be caused by several factors. For example, smoking, hypertension or 
hyperglycaemia triggers endothelial dysfunction by stimulating the expression of 
adhesion molecules for leucocytes in the endothelium. Leukocytes and lipids, carried 
by LDL-C particles, and macrophages can in this way infiltrate the intima. Fatty 
streaks, eventually starting to protrude into the arterial lumen, are formed as the 
macrophages ingest LDL-C particles and develop into foam cells. A fibrous cap is 
formed over the fatty streak as smooth muscle cells, from the tunica media migrate 
into the intima and start to release extra cellular matrix molecules. At this stage, the 
damage is no longer reversible. Over time, the plaque continues to progress and 
develops into an advanced lesion characterized by a dense fibrous cap and underlying 
haemorrhage and apoptotic cells. The plaque growth will eventually lead to significant 
narrowing of the arterial lumen, which may cause ischemia (manifested as angina 
pectoris) during periods of physical or psychological stress. Pro-inflammatory 
cytokines can stimulate macrophages and other cell types to release 
matalloproteinases (MMPs), which are enzymes capable of catabolizing 
macromolecules of the arterial extracellular matrix. This in turn may cause a plaque 
rupture leading to clinical significant thrombus formation, manifested as an ACS.81, 
85The fibrous cap of ruptured plaques are generally thin, which has been proposed to 
be caused by the impaired collagen synthesis of smooth muscle cells as a consequence 
of inflammatory signals.85Superficial erosion of the intima is another mechanism 
precipitating ACS in which a potential involvement of inflammation is not clear.  
Since inflammation is involved in many steps of the atherogenic process and affecting 
both extent and composition of the atherosclerotic plaques, the potential use of 
various inflammatory biomarkers in predicting clinically significant CAD, such as ACS, 
has been researched. White blood cell (WBC) count, TNF-α, CRP86 and various 
cytokines are examples of biomarkers that have been associated with CV events. TNF-
α and CRP87predict CV events independent of each other and present traditional risk 
factors. Furthermore, TNF-α is associated with short-term risk of CV events. Since 
neither of these biomarkers are specific to atherosclerosis, but are also mediators in 
several other conditions, including RA, their role in clinical praxis remains to be 
determined. RF has been associated with an increased risk of CVD in the general 
population,88-91but there is no clear role of its involvement in the pathogenesis of CVD. 
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Similarly ACPAs have also been associated with an increased risk of CVD in non-RA 
subjects.92 
2.2.1.3 Acute coronary syndrome – symptoms and treatment 
Acute coronary syndrome is stratified into acute ST-segment elevation MI (STEMI), 
unstable angina pectoris (UA) or non-ST segment elevation MI (NSTEMI) based on 
symptoms, electrocardiogram (ECG) and cardiac biomarkers. The pathophysiology of 
the different subtypes of ACS differs, as does the risk stratification and treatment, 
between them.93 Four pathophysiological processes contribute to the development of 
UA/NSTEMI, which is caused by a reduced oxygen supply to the myocardium and/or 
an increased myocardial oxygen demand: i) a rupture or erosion of non-occlusive 
thrombus, ii) coronary spasm, iii) rapid progression of atherosclerosis or restenosis 
following percutaneous coronary intervention (PCI) causing mechanical obstruction, 
and iv) increased oxygen demand or reduced oxygen supply caused by another 
condition, for example tachycardia or anaemia, causing UA. UA is diagnosed based on 
characteristic ischemic symptoms in the absence of evidence of myocardial necrosis 
(as measured by a cardiac biomarker). Symptoms of UA in combination with ECG-
findings and elevated cardiac biomarkers define NSTEMI. STEMIs are typically caused 
by a total thrombotic occlusion of a coronary artery. Usually, the thrombus has 
developed rapidly at the site of a vascular injury, and a collateral network has not had 
time to develop. Patients with STEMIs typically present with a more intense, often 
radiating, pain compared to UA/NSTEMI, or even dyspnoea or syncope. Importantly, 
there are patients presenting with painless STEMIs, which is more common in 
patients with diabetes and in the elderly. STEMI are characterised by elevated cardiac 
biomarkers and typical ECG-changes.  
Primary PCI is the gold standard treatment for STEMI94 and intermediate or high risk 
UA/NSTEMIs, whereas low risk UA/NSTEMIs are usually treated conservative with 
anticoagulants.95 Several factors have been identified as important predictors for 
outcomes following ACS, and there are several tools that can be used to identify high 
risk patients. The Killip classification is a bedside assessment of risk based on clinical 
signs of HF in patients with ACS, which is convenient to use in clinical practice. 
Higher Killip class scores are associated with increased short- and long-term mortality 
following ACS. Inflammatory activity has been associated with adverse outcomes 
following ACS in the general population.96, 97 The gold standard of secondary 
preventive pharmacotherapies includes aspirin, P2Y12-inhibitors, beta-blocking 
agents, RAS-blocking agents and statins.98 Usage of these drugs is associated with an 
improvement in the long-term mortality and morbidity after ACS.  
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2.2.2 Heart failure  
Heart failure is a complex clinical syndrome with a high prevalence especially in the 
elderly, and is associated with substantial morbidity.  
Various conditions are capable of altering the structure of the left ventricle (LV) and in 
this way predisposing the development of HF which is classified into HF with reduced 
ejection fraction (EF) (HFREF) and HF with preserved EF (HFPEF).99 Some aetiologies 
overlap and may predispose both subtypes of HF, whereas others are more specific to 
either subtype. Coronary artery disease and hypertension are the most common risk 
factors for HF in western countries, and can lead to the development of both HFREF 
and HFPEF. In addition to the established risk factors for HF, the association between 
inflammation and HF has recently been recognized. Several proinflammatory 
biomarkers are elevated in HF, but it remains unclear whether the association 
between inflammation and HF reflects a causal effect between inflammation and 
HF.100   
Symptoms and clinical signs of HF include dyspnoea, decreased exercise tolerance, 
paroxysmal nocturnal dyspnoea, orthopnoea, pulmonary rales, oedema, abdominal 
pain, etc. The New York Heart association (NYHA) Classification for HF groups HF 
into levels of severity based on the level of physical activity. HF is diagnosed based on 
the typical symptoms in combination with laboratory biomarkers and 
echocardiography so as to determine the aetiology and subtype of HF.  
Treating HF includes treatment of the underlying conditions as well as specific HF-
treatment including diuretics, RAS-blocking agents and beta-blockers.  
 
2.3 CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS  
2.3.1 The risk of CVD in RA 
A meta-analysis of observational studies on the risk of CVD in RA found a pooled 
relative risk (RR) of 1.48 for CVD overall.4 RA has been associated with most subtypes 
of CVD and, of the various CVDs, IHD and in particular MI has been most extensively 
studied. The incidence101 and prevalence102 of IHD in RA is increased and in various 
cohort studies, RRs of IHD in RA between 1.5 and 3 have been reported.103-109 The risk 
of IHD seems to develop rather rapidly after RA-onset 110, 111 and is increased in both 
men and women. Furthermore, the risk of ACS has, despite improvements in RA 
treatment and disease control,112 remained constant over time.113 
In contrast to IHD, not many studies have addressed HF in RA. However, 
retrospective cohort-studies have indicated an increased life-time prevalence of HF in 
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RA,114, 115 as well as a doubled RR of incident HF in RA 76, 116-118 and increased HF-related 
mortality.118 
RA has also been associated with an increased risk of cerebrovascular disease,4, 119 
venous thromboembolism,120 certain cardiac arrhythmias121, 122 and peripheral arterial 
disease.123  
2.3.2 Risk factors for CVD in RA 
As we have seen, the pathophysiological mechanisms of the inflammation 
characteristic for RA and the involvement of inflammation in the atherogenic process 
share many features. Inflammatory cells, such as macrophages, mast cells and T-cells 
are activated in both atherosclerosis and in RA. Furthermore, the production of TNF-
α, various cytokines and leukocyte adhesion molecules are also similar.84, 124, 125 In 
addition to promoting the initiation and progression of atherosclerosis, inflammation 
promotes development of vulnerable plaques prone to rupture. The structure of 
atherosclerotic lesions in RA shows more signs of inflammation and instability 
compared to non–RA subjects.126, 127 
The traditional CV risk factors influence the risk of CVD in RA, especially when 
potentiated by inflammatory activity.128 However, their presence cannot explain the 
overall risk increase of CVD in patients with RA.129, 130 Given the similarities between 
RA-related inflammation and atherosclerotic disease, markers of the RA-related 
inflammation have been assessed as potential risk factors. Elevated levels of CRP and 
ESR have been associated and an increased risk of subclinical CVD, CVD115, 116, 131-133 and 
CVD-related mortality in RA 132-135. Other indications of severe RA disease, such as 
extra-articular manifestations and high disease activity have also been associated with 
an increased risk of CVD116, 128, 132, 133, 136, 137 and CV-related mortality. Low functional 
status, measured using HAQ has also been associated with CVD133 and CV-related 
mortality.133, 138 
Several studies have associated RF-positivity with an increased risk of clinically 
significant CVD in RA132, 133, 135, 138, 139, whereas one study comparing two different 
cohorts from different time periods found an association with RF-positivity and CVD 
in the older cohort, but failed to replicate the association in the more recent cohort.101 
There is no established exact role for RF in the development of CVD, why it remains 
unclear whether RF itself actually influences the risk of CVD or if RF-positivity reflects 
the higher disease activity and inflammatory activity in this subgroup of RA patients. 
ACPAs are newer autoantibodies used in the diagnosis and classification of RA and 
fewer studies have addressed their potential role as a RA-related risk factor for CVD. 
However, ACPA-positivity has been associated with an increased risk of CVD in the 
general population92as well as an increased risk of IHD in RA.140ACPA-positivity in RA 
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has also been associated with an increased risk of subclinical manifestations of CVD, 
such as structural myocardial abnormalities and more substantial atherosclerotic 
lesions.141RA has also been associated with a higher degree of citrullination of the 
myocardial interstitium compared to non-RA subjects. No observational study has 
assessed the impact of fine-specific ACPA-titres and the risk of CVD. However, specific 
ACPAs have been associated with markers of endothelial dysfunction and overall 
atherosclerotic burden.142  
Various genetic markers have also been associated with the increased risk of CVD in 
RA. The HLA-DRB1*0404 and 2 alleles of HLA-DRB1*0104 have been associated with 
an increased risk of CVD and CV-related mortality in RA.132, 143, 144 Polymorphisms of 
several genes have also been associated with an increased risk of CVD in RA.145-149  
Treatment with MTX has been associated with a decreased risk of CVD in RA,150 
whereas assessments of the impact of glucocorticoids on the CV risk has been 
inconclusive.151It is unclear whether the association between MTX and reduced CV risk 
is caused by a direct effect on atherosclerotic lesions or reflects the reduction in RA-
related inflammation.  
These previously published studies of risk factors for CVD and CV-related mortality in 
RA are summarized in table 2.1. The vast majority of these studies have used CVD as a 
composite outcome including several subtypes of the disease.  
A few additional studies have addressed potential risk factors for HF RA (summarized 
in table 2.2). In similarity with studies on CVD overall, high inflammatory activity 
measured using ESR or CRP, high DAS28, RF-positivity and other signs of severe RA 
have been associated with an increased risk of HF.115-117 None of the studies distinguish 
between different types of HF.  
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Table 2.1 Previously published studies of risk factors for cardiovascular disease and cardiovascular death in rheumatoid arthritis (not 
including papers with drugs as main exposure/s). 
 
AUTHOR 
 
YEAR OF RA-
DIAGNOSIS 
 
STUDY 
DESIGN 
 
INCIDENT RA 
 
DISEASE 
DURATION 
 
MEAN/MEDIAN 
FOLLOW-UP 
MEAN/ 
MEDIAN 
AGE AT STUDY ENTRY 
 
OUTCOMES 
 
RISK FACTORS 
 
RELATIVE RISK 
(95% CI) 
Farragher 143 1989 - 1994 Cohort Yes 5 (2-12) mo N/A 55 (41-66) CV Death HLA-DRB1 HR 3.0 (1.4-6.7)C 
Gonzalez-Gay132 N/A Cohort  No  8 (4-14) yr 13 (10-16) yr 61 (51-70)  
 
CVD 
RF+B HR 2.4 (0.7-7.9) 
Mean CRPB HR 1.1 (1.0-1.1) 
Mean SRB HR 1.0 (1.0-1.1) 
ExRA HR 1.7 (0.9-3.4) 
HLA-DRB1  HR 1.8 (0.9-3.6) 
 
 
CV Death 
RF+B HR 3.2 (0.4-24.9) 
Mean CRPB  HR 1.1 (1.1-1.2) 
Mean SRB HR 1.1 (1.0-1.1) 
ExRA HR 1.8 (0.7-4.7) 
HLA-DRB1*04  HR 4.2 (1.2-15.0) 
Goodson134 A 1990-1992 Cohort  Yes 5.5 (2.9-12) mo 10 (9-11) yr 55 (42-68)  
CV Death 
 
CRP ≥ 16B 
Men HR 4.0 (1.1-15.2) 
Women HR 3.0 (0.9-
9.8) 
RF+ HR 6.4 (1.3-30.8) 
RF- 2.2 (0.7-7.0) 
Radovits136 1985 – N/A Case-
control 
Yes  N/A N/A N/A  CVD  DAS28 Baseline OR 1.2 (0.6-2.4) 
DAS28 AUC OR 1.1 (0.8-1.4) 
Innala128 
 
1995-2008 Cohort Yes 6.6 ± 3.3 mo 5 yr 55 ± 14  
 
CVD  
DAS28  
AUC 6mo 
HR 1.01 (1.0-1.1) 
DAS28  
AUC 6 mo  
+ HT present 
HR 3.6 (2.0-6.4) 
Ajeganova133 1993-1999 Cohort Yes N/A 13 (2-17) yr 55 ± 15  
 
CVD 
CV Death 
RF+B HR 1.2 (0.9-1.6) 
       CRP AUC 2 yrs HR 1.0 (1.00-1.1) 
       ESR AUC 2 yrs  HR 1.0 (1.0-1.1) 
       DAS28 AUC 2 
yrs 
HR 1.0 (1.0-1.1) 
       HAQ AUC 2yrs HR 1.1 (1.0-1.3) 
       GC HR 1.7 (1.2-2.3) 
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Table 2.1 Continued. 
 
AUTHOR 
 
YEAR OF RA-
DIAGNOSIS 
 
STUDY 
DESIGN 
 
INCIDENT RA 
 
DISEASE 
DURATION 
 
MEAN/MEDIAN 
FOLLOW-UP 
MEAN/ MEDIAN 
AGE AT STUDY 
ENTRY 
 
OUTCOMES 
 
RISK FACTORS 
 
RELATIVE RISK (95% 
CI) 
Farragher138A 1990-1994 Cohort Yes 4 (2-10) mo 10.3 (10.1-10.8) yr 54 (41-66) CV Death HAQB HR 1.2 (0.9-1.6) 
HAQ year 1 HR 1.6 (1.2-2.1) 
RF+ HR 2.2 (1.4-3.5) 
DAS28B HR 1.1 (1.0-1.3) 
DMARD-
treatment yr1 
HR 1.6 (1.0-2.5) 
Maradit-
Kremers135 
1955-1995 Cohort Yes N/A 15 ± 10 yr 58 ± 15 CV Death ESR >60D HR 2.1 (1.6-2.9) 
RF+ HR 1.6 (1.2-2.3) 
Destructive 
changes x- rayD 
HR 1.4 (1.0-2.0) 
Rheumatoid 
nodulesD 
HR 1.6 (1.1-2.2) 
Davis152 1955-1995 Cohort Yes N/A 13 (8-21) yr 58 ± 15 CVD 
CV Death 
GC >7.5mg/day 
(vs. no GC) 
All HR 2.0 
(1.3-3.3) 
RF+ HR 3.1 
(1.7-5.6) 
Wallberg-
Jonsson131 
1974-1979 Cohort Yes <1yr N/A 52 CVD 
 
 
ESRB HR 1.0 (N/A) 
ESR 5yr HR 1.0 (N/A 
HLA-B27 HR 2.2 (N/A) 
Early GC-
treatment 
HR 2.34 (N/A) 
1-2 DMARDs HR 0.9 (N/A) 
>2 DMARDs HR 0.4 (N/A) 
Teruel145 N/A Case-
control 
No N/A 11 ± 8yr 54 ±  15 CVD ACP1 
polymorphism 
OR 2.6 (1.2-5.5) 
Ärlestig153 N/A Case-
control 
No 16 ± 12 yr 3yr 62 ± 13 62 ± 13 
IHD 
DVT/PE 
TNFRII 
PAI-I 
FXIIIA 
OR 1.6 (1.1-2.4) 
OR 2.6 (1.1-6.4) 
OR 4.9 (1.3-17.9) 
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Table 2.1 Continued  
 
AUTHOR 
 
 
YEAR OF RA-
DIAGNOSIS 
 
STUDY 
DESIGN 
 
INCIDENT RA 
 
DISEASE 
DURATION 
 
MEAN/MEDIAN 
FOLLOW-UP 
MEAN/ 
MEDIAN 
AGE AT STUDY ENTRY 
 
OUTCOMES 
 
RISK FACTORS 
 
RELATIVE RISK 
(95% CI 
Mattey144 1986-1997 Cohort No 6 (4-11) yr N/A 57 (45-66) CV Death DRB1 – 2 
alleles 
HR 2.0 (1.0-3.9) 
Panoulas148 2004-2006 Cohort No 10 (4-18) yr N/A 63 (56-70) CVD  IL-6-174G/C 
Polymorphism 
OR 1.9 (1.0-3.6) 
Panoulas146  Case-control No 10 (4-18) yr N/A 63 (56-70) CVD Lymphotoxin 
252A>G 
Polymorphism 
OR 2.6 (1.1-5.9) 
Palomino-
morales149 
1996-2006 Case-control No N/A 14 ± 9 yr N/A CVD MTHFR 
A1298C 
Polymorphism 
5 yr OR 1.5 (1.0-2.1) 
10 yr OR 1.6 (1.1-
2.4)  
Gonzalez139 1955-1995 Cohort Yes N/A 16 yrs RF+ 57  
RF- 60 
CV Death RF RF+ SMR 1.4 (1.0-
1.9) 
RF- SMR 1.0 (0.7-
1.4) 
Turesson137 1939-2001 Cohort No N/A N/A N/A CVD ExRA HR 3.8 (2.0-7.2) 
Kapetanovic154 1985-1989 Cohort Yes 11 ± 7 mo N/A 51 ± 12 CVD 
 
AUC 
CRP/ESR/DAS  
yr 1/1-2/0-2 
 
No association  
DMARDs yr 
1/1-2/0-2 
No association  
GC yr  
1/1-2/0-2 
No association 
López-Longo140 1988-2003 Cohort No 11 ± 8 yrs N/A 52 ± 13 IHD ACPA+ OR 2.6 (1.2-5.7) 
AInflammatory polyarthritis B At baseline/study recruitment CHLA-DRB1*01|*04 compared to 0 or 1 SE allele *Symptom duration for inception cohort and disease duration for prevalent non-inception 
cohorts. DTime-dependent covariates 
mo, months; yr, years; HR, Hazard ratio; OR, Odds ratio; SMR, standardized mortality ratio; CVD, cardiovascular disease; IHD, ischemic heart diseae; PE, Pulmonary embolism; DVT, deep venous 
thrombosis; HT, hypertension; DAS28, Disease activity score: HAQ, Health assessment questionnaire; GC – Glucocorticoids; DMARD, disease modifying antirheumatic drug; ExRA, extra articular disease 
manifestations; RF+,Rheumatoid factor positivity; RF-, rheumatoid factor negativity  
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Table 2.2 Previously published studies of the relative risk of heart failure in rheumatoid arthritis 
Author/s Country Year of 
RA-
diagnosi
s 
Study Design Study Size Incident/ 
Prevalent RA 
Mean/Median 
age at study 
entry 
Mean/Median FUP Outcomes Prevalence/ 
Incidence rate 
Relative risk 
(95% CI) 
Wolfe USA <1999 Retrospective 
cohort-study 
NDBA 
9093 RA 
2470 OA 
N/A 
 
RA – 59.8 ± 13.0 
OA – 66.0 ± 11.2 
N/A (self-reported) 
 
HF lifetime 
Prevalence 
(/100 pts) 
RA 2.3(2.0-2.8) 
OA 1.6 (1.5-1.8) 
OR 1.4 (1.3-1.6) 
Myasoedova USA 1980-
2008 
Population-
based cohort-
study 
REPB 
795 RA Incident 55.3 ± 15.5 9.7 ± 6.9 yrs (Framingham)C 
Incident HF 
N/A RF+ HR 1.6 (1.0-2.5) 
Incident ESR ≥60 
HR 1.6 (1.2-2.0) 
Repeat ESR ≥60 
HR 2.1 (1.2-3.5) 
Severe ExRA 
HR 3.1 (1.9-5.1) 
RA < 1 yr 
HR 2.0 (1.1-3.8) 
DAS28>2.6 
Schau Germany N/A Prospective 
cross-sectional 
157 RA 
77 matched 
controls 
N/A 
 
RA 61 ± 13 
Controls 59 ± 12 
 
N/A Prevalent HF N/A OR 3.4 (1.3-9.8) 
RA-duration >10yrs 
OR 2.6 (1.2-5.8) 
CRP median >10 
OR 4.8 (1.1-21) 
ESR >16 
OR 5.4 (2.1-16) 
Nicola USA 1955-
1995 
Population-
based 
retrospective 
cohort 
575 RA 
583 Non-RA 
Incident RA 57 ± 15 
Non-RA 57 ± 15 
Median (iqr) 
RA 12(7-20) yrs 
Non-RA 14 (8-23) yrs 
Incident HF IR (/100 pyrs) 
RA 1.99 
Non-RA 1.16 
All HR 2.0 (1.5-2.5) 
RF+ HR 2.5 (1.9-3.3) 
RF- HR 1.4 (1.0-2.0) 
Nicola USA 1955-
1995 
Population-
based 
retrospective 
cohort 
603 RA 
603 non-RA 
Incident RA 58 ± 15 
Non-RA 58 ± 15 
Median 
RA 13 yrs  
(8842 pyrs) 
Non-RA 15 yrs (10101pyrs) 
Incident HF IR(/1000pyrs 
RA 19 (16-22) 
Non-RA 12 (10-14) 
Chf-related mortality 
RA HR 4.9 (3.8-6.1) 
Non-RA HR 4.3 (3.3-5.5) 
Gabriel USA 1965-
1985 
Population-
based cohort 
450 RA 
450 controls 
Prevalent RA 64.1 
Controls 67.5 
N/A HF RA 17.3 % 
Controls 12.0% 
1.60 (1.12-2.27) 
ANational data bank for rheumatic diseases. Enrolled patients receive survey at 6 month intervals.BRochester epidemiology project. CFramingham heart failure criteria: 
HF, Heart failure; RA, rheumatoid arthritis; OA, Osteoarthritis; OR, odds ratios; pts, patients; RF+, Rheumatoid factor positivity; HR, Hazard ratio; ExRA, Extraarticular RA; yrs, Years; PYRS, person-years; MI, Myocardial infarction  
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2.3.3 Clinical presentation  
As the development of CVD in RA seems to be, at least partly, driven by factors other 
than the traditional CV risk factors and inflammatory activity has been linked to the 
severity of ACS and more extensive coronary atherosclerosis, 155patients with RA might 
hypothetically experience a different clinical phenotype of ACS compared to non-RA 
patients. Few studies have addressed the clinical presentation of ACS in RA and the 
existing scarce results are inconclusive. Nevertheless, patients with RA have been 
reported to present with atypical symptoms more often as well as experiencing silent 
MI, collapse or sudden cardiac death more frequently compared with non-RA 
patients.107, 156 In contrast, no difference other markers of severity such as Killip class or 
NSTEMI vs. STEMI has been reported157 (summary of previous studies of clinical ACS-
presentation in table 2.3).  
RA has also been associated with a subtler presentation of HF and higher frequencies 
of HFREF compared with non-RA patients.158  
2.3.4 Outcomes  
Inflammatory activity has been linked to adverse outcomes following ACS in the 
general population.96, 159, 160Studies investigating short-term outcomes following ACS 
have reported both no differences157 as well as increased short-term mortality in RA 
compared to non-RA patients.105, 161An increased risk of long-term mortality and 
recurrent events in patients with RA with ACS compared to non-RA patients with ACS 
(summary of previous studies of outcomes following ACS in RA in table 2.3).156, 157, 162  
2.3.5 Follow-up care 
Follow-up care after ACS aims to prevent further CV events, and consists of 
modification of risk factors using pharmacotherapies and other preventive 
measurements as discussed in the previous section. Few studies have assessed the 
usage of secondary preventive drugs in patients with RA following ACS. One case-
control study has reported that the in-hospital usage of beta-blocking agents and 
lipid-lowering agents was lower among RA-patients compared to population controls, 
163 whereas another study of in-hospital treatments could not detect a difference.157 
Lower rates of initiation and adherence to aspirin, beta-blocking agents and lipid-
lowering agents were also observed in a nationwide Danish cohort-study.164 
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Table 2.3 Previous studies assessing clinical ACS characteristics and outcomes following ACS in patients with RA.  
 
Authors 
 
Study 
Design 
 
Study size 
 
Year of event  
 
Outcome/s 
 
 
Follow-up 
 
Relative risk 
Case-fatality 
Clinical characteristics 
outcomes 
 
Difference/Relative risk clinical characteristics 
Maradit-
Kremers107  
Cohort 603 RA-subjects 
and 603 
comparators  
 
 
 
 
Fup 2001  Incident CHD 
Information 
retrieved from 
medical records  
RA: 14.7 yrs 
Non-RA: 16.8 
yrs 
 
 
NOT ASSESSED 
 
Unrecognized MIA HR 2.20 (1.18-4.18) 
PTCA HR 1.77 (0.92-3.41) 
CABG HR 0.35 (0.16-0.78) 
Sudden death HR 2.36 (1.30-4.27) 
Reporting angina 
symptoms 
HR 0.76 (0.52-2.12) 
Douglas156 - 40 RA-patients  
40 Controls with 
incident ACS 
1990-1999 Clinical 
presentation, 
All-cause mortality, 
CV-mortality and 
recurrent cardiac 
events.  
Collected from 
medical charts and 
death certificates.   
31st Dec 2001  Chest pain RA 82% vs. controls 100 % (p=0.003) 
Death  
(All-cause) 
RA 48% vs. controls 
25%  
(p=0.036) 
Dyspnoea NS 
CV-Death RA 40% vs. controls 
15%  
(p=0.012) 
Collapse RA 18% vs. controls 3% 
(p=0.025) 
Recurrent ACS RA 45% vs. controls 
25% 
(p=0.011) 
Arrhythmia  NS 
  Killip Class NS 
Södergren105 Cohort 35 RA-subjects 
and 105 
matched 
controls with 
incident MI 
  
 
All-cause mortality  
24 h HR 1.26, p=0.58 Typical ECG-signs RA 17% vs. controls 34% 
28 days HR 1.43, p=0.27 
5 yrs HR 1.56, p=0.11   
10 yrs  HR 1.67 (1.02-2.71) 
McCoy157 Cohort 77 RA-subjects 
and 154 
matched 
controls with MI 
1979-2009 All-cause mortality Hospitalization RA 5% vs. comp 8%  
(NS) 
Killip class II-IV 
 
RA 36% vs. Comparators 35% (NS) 
30 Days RA 6% Comp 12% 
OR 0.41 (0.13-1.31) 
STEMI RA 21% vs. Comparators 28% (NS 
FUP 
RA med 2.6yr 
Comp 2.7 yr 
HR 1.47 (1.04-2.08) Revasc. Procedures OR 1.19 (0.63-2.23) 
Recurrent event  HR 1.51 (1.04-2.18)   
Heart failure  30 Days NS   
5 yrs RA 57% vs. comp 
35% (NS) 
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Table 2.3 Continued  
 
Authors 
 
Study 
Design 
 
Study size 
 
Year of event  
 
Outcome/s 
 
 
Follow-up 
 
Relative risk 
Case-fatality 
Clinical characteristics 
outcomes 
 
Difference/Relative risk clinical characteristics 
Van 
Doornum161 
Cohort 359 RA 
29924 
comparators 
2001-2003 All-cause mortality 
after MI 
30 Days OR 2.3  (1.6-3.1) 
Adj.OR 1.8 (1.3-2.6) 
CHF during 
hospitalisation 
OR 1.6 (1.2-2.1) 
Ajd OR 1.2 (0.9-1.7) 
PTCA  OR 0.4 (0.3-0.7) 
CVD mortality after 
MI 
30 Days OR 2.3 (1.7-3.2) 
1.9 (1.3-2.7) 
CABG  Insufficient sample size 
ICU/CCU  OR 0.6 (0.5-0.8) 
Van 
Doornum163 
Cohort  90 RA patients 
90 comparators 
1995–2005 (medical chart 
review) 
 
  
 
NOT ASSESSED 
Acute reperfusion OR 0.27 (0.1-0.6) adj OR 0.21 (0.1-0.6) 
Thrombolysis OR 0.3 (0.1-0.8) adj OR 0.3 (0.1-1.0) 
PCI OR 0.2 (0.1-0.5) adj OR 0.2 (0.1-0.6) 
PCA OR 0.4 (0.2-0.9) adj OR 0.2-1.3) 
CABG OR 0.6 (0.2-1.5) adj OR 0.3 -1.7) 
AUnrecognised MI defined as presence of characteristic ECG-findings in non-acute setting 
CHD, coronary heart disease; MI, Myocardial infarction; ACS, acute coronary syndrome; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting 
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3 RATIONALE FOR THE SPECIFIC SUB-STUDIES 
3.1 STUDY I – RISK FACTORS FOR ACS IN RA 
Firstly, most previous studies assessing potential risk factors for CVD in RA are based 
on older cohorts, making the results difficult to extrapolate to the contemporary RA-
patient, with an in comparison more modern and different treatment regime. 
Secondly and importantly, the vast majority of these studies have used CVD as a 
composite outcome, in which several subtypes of and also different combinations of 
subtypes of CVD have been included. Composite outcomes, such as CVD, are 
commonly used, especially in cardiovascular research, in order to increase the event 
rate and in this way also increase the statistical efficiency. Limitations using composite 
end points and difficulties in interpreting the results have repeatedly been pointed 
out165, 166 out, and several aspects must be considered when interpreting the results 
from studies using a composite outcome. The validity of the composite outcome partly 
depends on the number of events across components. Furthermore, using a composite 
outcome requires an underlying assumption of a similar underlying biological 
mechanism behind the association between the exposure and the respective 
component. Hence, the existing results from studies of risk factors for CVD in RA are 
difficult to relate to specific CV events, such as ACS.167  
The previous reported differences in time-to-risk between different types of CVDs in 
RA indicate that the pathophysiologies behind the risk increases are in fact at least 
partly different. It is possible that some of the risk factors are shared but contribute to 
the risk increases via different routes. For example, the risk of IHD seems to increase 
rapidly after RA-onset111, in contrast to the risk of cerebrovascular events, which 
develops later.168 Hypothetically, inflammation constitutes a risk factor for ACS by 
making existing atherosclerosis unstable or via other direct effects on the coagulation 
or coronary circulation. Long-term inflammation might instead lead to more extensive 
atherosclerosis and an increased risk of cerebrovascular events as a consequence.  
In Study I, we aimed to assess potential risk factors for ACS in RA in order to identify 
clinically usable and easily accessible predictors of the ACS-risk in patients with RA.   
 
3.2 STUDIES II AND III – CLINICAL CHARACTERISTICS AND OUTCOMES  
The results from Study I indicated that high inflammatory activity and disease activity 
soon after RA-onset triggers an increased risk of ACS in patients with new-onset RA. 
These results are in line with previous reports, and inflammation has also been shown 
to potentiate the effect of traditional CV risk factors in patients with RA.128 Given that 
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the risk of ACS in RA seems to be driven partly by factors other than the traditional 
CV risk factors, one might question whether the clinical phenotype of ACS in RA 
differs compared with ACS in non-RA patients (driven by traditional CV risk factors). 
As described in the background, inflammation affects the characteristics of the 
atherosclerotic plaque. Specific inflammatory cells and mediators are known to impair 
the collagen synthesis, which leads to thinner fibrous caps covering the atherosclerotic 
lesion.169Most severe and fatal MIs are typically caused by a ruptured thin cap.85 
Systemic inflammation also promotes thrombus accumulation by increased 
thrombogenicity. In the general population, the degree of inflammatory activity has 
also been linked to adverse outcomes following ACS.96  
Based on the above a priori knowledge of the impact of inflammation on the ACS 
phenotype we hypothesized that patients with RA differ in their clinical presentation 
of ACS in comparison with non-RA patients with ACS. Importantly, a different clinical 
presentation and increased risk of adverse outcomes might motivate a different risk 
stratification of this group of patients. Only a few previous studies have assessed the 
clinical characteristics and outcomes after ACS in RA, and their results have been 
inconclusive. Furthermore, most of these studies have been based on a small number 
of RA-patients and controls leading to statistical imprecision and difficulties in 
interpreting the results. There have, however, been indications, such as an increased 
risk of sudden cardiac deaths,107 that patients with RA suffer from more severe events 
and impaired short- and long-term outcomes.105, 107, 156, 157, 161  
With the apparent gap in our knowledge of clinical presentation and prognosis after 
ACS in RA in mind, we aimed at comparing these parameters in RA-patients 
compared to non-RA patients with ACS in Study II and Study III.  
An impaired outcome following ACS could, of course, have causes other than the 
clinical phenotype itself. As described in the background, usage of standard of care 
secondary preventive drugs is beneficial for, in particular the long-term prognosis 
following ACS. A difference in usage of secondary prevention between RA and non-RA 
patients with ACS could therefore potentially explain a difference in observed adverse 
long-term outcomes. As for studies on clinical characteristics and prognosis, few 
studies with conflicting results have assessed treatment following ACS in patients with 
RA. Two of these studies have assessed in-hospital treatment, and no information on 
usage thereafter, of various agents making the results difficult to extrapolate to long-
term outcomes.163 One larger cohort-study has assessed initiation and adherence to 
gold standard secondary preventive drugs following ACS during a two time periods of 
30 and 180 days following ACS. This study has, however, not taken the increased 
mortality rate among RA-patients into account in its design, which might lead to an 
underestimation of the drug usage among RA-patients due to a higher frequency of 
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deaths.164 Furthermore, none of the studies have assessed secondary preventive drug 
usage and mortality in the same study and have therefore not assessed mortality in 
groups with a known combination of drugs. In Study III, therefore, in addition to 
assessing long-term outcomes, we also investigated the usage of gold standard 
secondary preventive drugs following ACS in the RA patients compared to non-RA 
patients with ACS.  
 
3.3 THE RELATIVE RISK OF HEART FAILURE IN RA  
Heart failure is associated with substantial morbidity and mortality, and has several 
potential aetiologies. Hypertension and IHD are the most common causes of HF in 
high-income countries, and it is, therefore, no surprise that patients with RA, who are 
at increased risk of IHD also seem to suffer from an increased risk of HF. 
Inflammatory activity has been associated with HF, and it has been suggested that 
inflammation is not only a marker of disease, but rather a cause and is involved in the 
pathogenesis.100 For example, animal studies have shown that the inflammation in 
sepsis leads to myocardial depression.170 In addition, several of the inflammatory 
cytokines, such as TNF-α, associated with myocardial depression are also involved in 
the pathogenesis of RA.171  
Firstly, only a small number of studies have addressed the association between RA and 
HF, but they have all indicated an increased incidence, prevalence and HF-related 
mortality in RA. Hypothetically, the increased incidence of HF in RA could, in 
addition to developing after IHD, also be driven by RA-related inflammation or other 
factors directly. Yet, no study has investigated the risk of HF in RA in the presence and 
absence of IHD separately, or the impact of clinical markers of inflammation and 
disease activity on different HF subtypes. Based on these grounds, in Study IV we 
assessed the RR of ischemic and non-ischemic HF overall and in time periods before 
and after RA-onset as well as the impact of RA-related inflammation and disease 
activity.   
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4 OBJECTIVES 
4.1 OVERALL OBJECTIVES 
The overall objective of this thesis was to expand existing knowledge of the association 
between RA and specific CVD-types, CVD outcomes and CVD management.  
 
4.2 SPECIFIC OBJECTIVES  
The following specific aims have been addressed within the four sub-studies of this 
thesis:  
1. To identify risk factors for ACS in patients with new-onset RA Study I  
2. To describe the clinical characteristics of, and short-term mortality 
after, ACS in patients with RA Study II 
3. To assess the long-term recurrence and mortality following ACS in 
patients with RA, and to investigate whether usage of secondary 
preventive drugs differs in patients with RA compared to non-RA 
subjects Study III 
4.  To estimate the relative risk of ischemic and non-ischemic HF in RA 
and to assess the impact of RA disease activity on the HF risk  
Study IV 
 
 
Figure 4.1 Overview objectives 
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5 METHODS 
5.1 SETTING 
The long tradition of collecting and compiling information on the inhabitants in 
Sweden, initiated as early as in the 17th century, has paved the way for the existing 
national demographic and healthcare registers with nearly complete coverage. In 
combination with the structure of the Swedish health care system, these 
comprehensive register sources provide an excellent setting for conducting 
epidemiological research. Nevertheless, regardless of the extensive nature of the 
register sources there are many sources of potential bias to consider in 
epidemiological research, some of which are discussed in this section and others in the 
discussion section.  
Traditionally, Swedish health and welfare services have been tax-financed and have 
been considered a public responsibility, enabling equal access to all healthcare 
services. Maintaining the equity in the access to health care has been a growing reason 
for concern as health care gradually has moved toward an increased proportion of 
market-orientation.172 However, access to specialized care for chronic diseases such as 
RA and acute conditions such ACS, which is concentrated to hospital emergency, 
inpatient or outpatient care, still seems to remain equal173 and importantly enables 
identification of unselected population-based cohorts including patients with these 
conditions. Prescribed standard drugs are subsidized, and after reaching a fixed 
annual spending limit, all subsequent prescriptions are free of charge.174 
The Swedish personal identity number (PIN) was introduced in 1947, and since 1967 it 
has consisted of a six-digit birthdate followed by a four-digit identification number. 
The PIN, which is unique to the individual, is assigned by the Swedish tax agency to all 
inhabitants at birth or immigration if they are intending to stay for at least one year, 
and it can be used as an identifier in Swedish health care and other administrative 
areas. Immigrants with a shorter intended duration of stay will, if utilizing the 
Swedish social security system, instead be assigned a coordination number, and will 
not be included in national registers and thus not included in register-based studies 
such as the ones included in this thesis. In epidemiological research, the PIN can be 
used for linkage of different data sources.175 
 
5.2 DATA SOURCES  
Except for the national health registers, quality of care registers to evaluate and 
improve the quality of care for specific diseases of interest, such as RA and CVD, have 
been developed. Using the PIN as a key, information from these different register 
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sources can be linked together when researchers perform register-based 
epidemiological research. Data used in the studies of this thesis was collected from 
several national registers, quality registers and medical charts 
5.2.1 National registers  
National demographic registers are kept by Statistics Sweden, and the national health 
registers are kept by the National Board of Health and Welfare (NBWH).  
5.2.1.1 The total population register 
The total population register (TPR) contains demographic information such as birth, 
death, sex, residential care, civil status and information on migrations, and since 1968 
has been kept by Statistics Sweden.176 TPR was used to sample general population 
comparators in Studies II–IV.  
5.2.1.2 The National Patient Register 
The National Patient Register (NPR) has since 1964 contained information on in-
hospital care with complete coverage since 1987. Since 2001, NPR has also contained 
an outpatient part that includes visits to non-primary care with increasing coverage in 
the last few years (87% of all visits were reported in 2013). NPR holds information on 
admission, discharge dates and type of hospital department involved.177 Discharge 
primary and contributory diagnoses are coded according to the contemporary Swedish 
version of the International Classification of Diseases (ICD) system. The ICD10 coding 
system has been in use since 1997. Validity of many diagnoses, especially those of 
chronic and severe diseases, has been proven to be high in the NPR.178 NPR is a 
resourceful tool when conducting register-based research, and is used for identifying 
study subjects and/or outcomes of interest in all of the studies included in this thesis.  
5.2.1.3 The Cause of Death Register 
Information on death and causes of deaths in Sweden has been kept in the Cause of 
Death Register (CDR) since 1961.179 The international version of the ICD-system is used 
to code the supposed cause of death. CDR is also used in all studies included in this 
thesis.  
5.2.1.4 The Prescribed Drug Register 
Information on dispensed prescribed pharmacotherapies has been collected from the 
Prescribed Drug Register (PDR) since July 2005. The PDR contains information on the 
prescribed drug in the form of an Anatomical Therapeutic Chemical (ATC) code, 
name, dosage, expenditure, administration-route as well as information on the 
prescriber and the patient174. In Study I, PDR was used to identify certain exposures of 
interest, in Studies II and IV PDR was used to collect information on drug-status at 
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baseline that served as proxies for comorbidities of interest, and in Study III, where 
one of the outcomes was CV secondary preventive drug use, PDR was used to collect 
this information.  
5.2.2 Quality of care registers 
Both RA-specific and CVD-specific quality of care registers were used to obtain data 
used in the studies of this thesis.  
5.2.2.1 Swedish Rheumatology Register 
The Swedish Rheumatology Register (SRQ), initiated in 1995, includes patients with 
predominantly RA but also other rheumatic diseases diagnosed by rheumatologists. 
Initially, only patients with new-onset RA and patients on specific drugs were 
included, but the utility of the register has expanded over the years to include patients 
with established disease. SRQ contains information on disease duration, inflammatory 
activity and overall disease activity collected at pre-specified time points, and is used 
by rheumatologists to evaluate the disease-activity of their patients. SRQ includes over 
15,000 patients with new-onset RA.180 In Study I, SRQ was used to collect information 
on inflammatory activity and disease activity, which was combined with information 
retrieved from medical charts of the study subjects. In Study IV, SRQ was used to 
identify one cohort of patients with new-onset RA and for the study subjects of this 
cohort also to extract information on inflammatory and disease activity.  
5.2.2.2 RIKS-HIA 
RIKS-HIA RIS-HIA started as a regional register at the beginning of the 1990s and was 
established as a national quality of care register for heart intensive care in 1995. RIKS-
HIA is part of SWEDEHEART, which collects data for five separate registers aiming to 
support and improve the development of evidence-based therapies in acute and 
chronic coronary artery disease. Based on admissions to cardiac intensive care units, 
RIKS-HIA includes information on baseline characteristics, symptoms, in-hospital 
examinations, treatments, interventions, complications and discharge-status. 
Coverage has improved over the years and is generally higher in patients younger than 
80 (92% in 2015) compared to patients older than 80 (75% in 2015) due to different 
inclusion criteria for patients above 80 depending on geographical region181In Study 
IV, where one of the outcomes was clinical ACS characteristics, data were collected 
from RIKS-HIA.  
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5.2.3 Other data sources 
5.2.3.1 Epidemiological investigation of rheumatoid arthritis  
The epidemiological investigation of rheumatoid arthritis (EIRA) is a population-based 
case-control study of incident RA. The cases enrolled constitute patients between 18 
and 70 years of age diagnosed with new-onset RA by rheumatologists from clinics in 
central and southern Sweden. Questionnaires are used to collect information on 
health status, lifestyle related factors and environmental exposures. Blood samples are 
drawn for analysis of autoantibodies and DNA extraction. For each case, a control is 
sampled using the TPR and matched on sex, age and area of residency. As for all the 
cases, participating controls are asked to complete the questionnaire and provide a 
blood sample 33. In Study I, both cases and controls were sampled from the cases 
included in EIRA. Information on certain CV risk factors, as reported on the 
questionnaires, autoantibodies and selected genetic markers was also extracted from 
EIRA. 
5.2.3.2 Medical charts  
All health care personnel are by law obligated to document everything concerning the 
patients’ health status related to the health care visit or hospitalization in the patient’s 
medical record, which is individually linked to the patient via the PIN. The medical 
record should include relevant background information as well as diagnoses, 
assessments, laboratory measurements, examination findings, treatments, etc. 182Apart 
from being an important clinical instrument ensuring patient security and useful for 
health care evaluations, the medical chart is also a useful research tool and can be 
used to validate  information from other register sources as well as providing detailed 
information on variables of interest. In Study I, medical charts for all study subjects 
were retrieved so as to validate the outcome as well as collect information on selected 
disease variables.  
 
 
 
 
 
 
Figure 5.1 Overview of data sources included in the respective study. 
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5.3 STUDY POPULATIONS AND STUDY DESIGNS 
5.3.1 Overview 
The different aims of the four sub-studies required slightly different definitions of RA 
with/without ACS (the exposure) to suit the specific objective/s with the respective 
study.  
Exposures, outcomes and other covariates of interest have all been collected from the 
various data sources described in the previous section. This register-based setting is 
very different from the clinical setting where the physician has direct access to the 
patient and thereby can confirm the different variables of interest direct. Although 
diagnoses and/or drugs registered in the national health registers readily can be used 
as proxies in register-based research, it is crucial using well-deliberated definitions to 
avoid introducing bias. The different definitions of RA used in the sub-studies are 
either based on inclusion in SRQ or EIRA (as reported by rheumatologist) or on 
validated diagnostic algorithms using the NPR. Incident RA is defined as new-onset 
RA, whereas prevalent RA is defined as established disease including patients with 
various disease durations.  Outcomes (ACS, IHD and HF) have typically been captured 
using the NPR and/or CDR where most diagnoses have a high reported validity. See 
table 5.1 for detailed information on validity on respective exposure and outcome used 
in the different studies.  
Table 5.1 Overview of validity of exposures and outcomes of the respective study.  
STUDY   DIAGNOSIS 
DEFINITION 
REFERENCE GOLD 
STANDARD 
VALIDITY COMMENTS 
STUDY POPULATION/EXPOSURE 
STUDY I  
 
Incident RA in 
EIRA 
N/A N/A N/A Patients are 
diagnosed and 
included by 
rheumatologists 
STUDY II 
& III 
Prevalent RA in 
the national 
patient register 
 
Waldenlind et 
al. 183 
Medical 
charts 
PPV ≈ 
90% 
Fulfilment of 2010 
ACR/EULAR 
classification 
criteria 
STUDY 
IV 
 
 
 
  
Prevalent RA the 
national patient 
register 
Waldenlind et 
al. 183 
 
Medical 
charts 
PPV ≈ 
90% 
Fulfilment of 2010 
ACR/EULAR 
classification 
criteria 
Incident RA in the 
Swedish 
rheumatology 
registe 
N/A N/A N/A Patients are 
diagnosed and 
included by 
rheumatologists 
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Table 5.1 Continued  
STUDY DIAGNOSIS 
DEFINITION 
REFERENCE GOLD 
STANDARD 
VALIDITY COMMENTS 
OUTCOMES 
STUDY I, 
II and III  
ACS = Main 
diagnosis of ACS 
(MI or UAP)  
Linnersjö et 
al. 184 
Ljung et al. 185 
Medical 
charts  
PPV = 
>95% 
 
STUDY 
IV  
HF overall = Main 
diagnosis of HF in  
Ingelsson et 
al. 186 
Medical 
charts 
PPV = 
>95% 
 
Ischemic HF =  
Main diagnosis of 
HF in NPR in 
patients with an 
antedating 
diagnosis of IHD or 
specific ICD-code 
indicating ischemic 
HF   
 
N/A N/A N/A The exact 
definition used 
has not been 
validated. 
However, HF186 
and IHD184 have 
separately 
been reported 
to have high 
validity.   
Nonischemic HF =  
Main diagnosis of 
HF in NPR in 
patients without 
an antedating 
diagnosis of IHD 
N/A N/A N/A The exact 
definition used 
has not been 
validated. 
However, HF186 
and IHD184 have 
separately 
been reported 
to have high 
validity.   
ACS, acute coronary syndrome; EIRA, epidemiological investigation of rheumatoid arthritis; HF, heart failure; PPV, 
positive predictive value; MI, myocardial infarction; NPR, national patient register; UAP, unstable angina pectoris 
 
 
 
5.3.2 Study I 
5.3.2.1 Study design 
Study I is a nested case-control study in which cases (subjects with RA and ACS) and 
controls (subjects with RA without ACS) were sampled among patients with incident 
RA included in the EIRA-study between 1996 and 2011. 
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5.3.2.2 Study population  
Cases were defined as subjects with incident RA included in EIRA between 1996 and 
2011 who, after the RA-diagnosis, developed an ACS during the follow-up. Between 
1996 and Dec 31th 2009, ACS was defined as a registered diagnostic code for ACS 
and/or intervention for ACS and/or CDR during the follow-up. This initial definition 
of ACS was validated against medical records, and cases which did not fulfil the 
diagnostic criteria for ACS as defined by the Joint European Society of 
Cardiology/American College of cardiology Committee187 were excluded. Validation of 
ACS showed, consistent with previous validations, a high predictive value for ACS 
identified using diagnostic code in NPR and/or CDR, whereas most events captured 
using intervention codes could not be classified as ACS (and hence were excluded). 
Therefore, only diagnostic code for ACS was used when identifying study subjects 
during an extended period of follow-up between 2010 and 2012.  
Controls were sampled from the same cohort of subjects with incident RA enrolled in 
EIRA between 1996 and 2011. Up to five unique controls, who did not develop ACS 
during the follow-up, were matched to each case using incidence density sampling 
(see box 5.1 for description of incidence density sampling) based on sex, year of RA-
diagnosis and EIRA-centre.  
Box 5.1 Incidence density sampling  
 
5.3.2.3 Exposures of interest  
Information on the exposures of interests (potential risk factors) was collected from 
several register sources in combination with information extracted from the medical 
charts. Table 5,2 provides an overview of these exposures and their respective data 
sources.  
 
 
Incidence density sampling  
Incidence density sampling is sometimes also referred to risk set sampling. The controls 
are selected from the entire at-risk source population at the time point as the case is 
identified (and are eligible to become a case during a later time point). The control serie 
provides an estimate of the proportion of the total person-time for exposed and 
unexposed in the source population. 
 
The advantages with incidence density sampling are that the odds ratio estimates the 
rate ratio and that the estimate is not biased due to differential loss of follow-up.1 
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Table 5.2 Exposures and their respective data source, Study I.  
EXPOSURE DATA SOURCE  
CV risk factors: BMI and Smoking at baseline EIRA 
CVD at baseline EIRA, Medical charts, NPR  
Disease activity during follow-up Medical charts, SRQ 
Autoantibodies, genetic markers EIRA 
RA Drugs Medical charts, PDR  
 
5.3.3 Study II and Study III  
5.3.3.1 Study design 
Studies II and III are cohort-studies based on the same cohort of prevalent RA 
patients with ACS and their matched general population comparators with ACS.  
5.3.3.2 Study population 
One cohort of prevalent (actively monitored) RA patients was identified each year 
between 2006 and 2009. Prevalent RA was defined as subjects above 18 years of age 
with i) at least two RA-diagnoses at in- or out-patient clinics, of which at least one of 
these visits at internal medicine or rheumatology clinic, or iii) listed in the SRQ. One 
of the visits had to occur in the years 2006, 2007, 2008 or 2009 to be defined as having 
actively monitored the disease in that particular year. Between 31,000 and 34,000 
subjects were identified each year using this definition and matched with up to five 
general population comparators based on year of birth, sex, educational level and area 
of residency using the TPR. Among the comparators, all subjects with a RA-diagnosis 
prior to the matching-year were excluded.  
Follow-up for identifying all subjects with ACS started the year following identification 
(i.e. the year in which the RA subjects were defined as having prevalent disease) 
between 2007 and 2010. All subjects with a diagnosis of ACS prior to start of follow-up 
were excluded. Subsequently, all subjects were followed via linkage with the NPR over 
one year so as to identify all subjects with a first ever hospitalization for ACS. ACS 
were defined as a main diagnosis of myocardial infarction or unstable angina. 
 A total of 1135 RA patients with incident ACS and 3184 general population 
comparators with incident ACS were identified between 2007 and 2010, and these 
made up the two study cohorts used for analysing outcomes of interest.  
5.3.3.3 Follow-up and outcomes 
Clinical characteristics  
 32 
Among the subjects with incident ACS in the NPR, all subjects also registered with 
ACS in RIKS-HIA within a time interval of -10 to +10 days following NPR-registration 
were identified. Information on clinical characteristics for these subjects was retrieved 
from RIKS-HIA. In order to characterize the clinical event information on status at 
admission (symptoms, blood pressure, heart rate, Killip class, ECG registration and 
biomarkers), in-hospital treatments (reperfusion if diagnosed as STEMI and 
anticoagulants if diagnosed NSTEMI), in-hospital complications and diagnosis at 
discharge were compiled, analysed and presented in Study II.  
Mortality 
Following the ACS, all subjects were followed in the CDR to identify all deaths 
following the ACS. Short-term mortality was defined as mortality during the first week 
and the first month following the ACS (Study II). For these deaths, the proportion of a 
specific underlying cause of IHD, HF and/or arrhythmias were also analysed in a 
sensitivity analysis. Long-term mortality (Study III) was defined as mortality during a 
follow-up of one year and during a longer follow-up period ending 31 Dec 2011 (Mean 
2.3 years).   
Recurrence 
As long-term mortality, recurrent ACS was analysed at one year and during the 
complete follow-up period ending 31th Dec 2011. Recurrent ACS was defined as an 
additional ACS-diagnosis in the NPR during follow-up starting at 30 days after the 
original ACS-date to avoid double-registrations from the same event.   
Secondary preventive drugs  
During the year following the ACS, usage of gold standard secondary preventive drugs 
(aspirin P2Y12-inhibitors, beta-blockers, RAS-blocking agents and statins) was 
analysed via linkage with the PDR. Initiation and subsequent usage of each drug was 
defined as the filled prescription of respective drug within four time periods (-7-90, 91-
180, 181-270, 271-365 days) after the ACS.  
5.3.4 Study IV  
5.3.4.1 Study design 
Study IV is a cohort study in which the relative risk of HF was assessed in two 
contemporary cohorts of RA patients compared to matched general population 
comparators.  
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5.3.4.2 Study population 
Two separate cohorts of RA patients, one population-based cohort with subjects with 
prevalent disease and one cohort of subjects with incident disease, were identified. 
The NPR was used to identify the prevalent cohort using a similar algorithm as in 
Studies II and III. All subjects 18 years or older with at least two visits listing RA, of 
which at least one visit at internal medicine or rheumatology clinic, at inpatient or 
outpatient clinic between 2006 and 2012, were identified. The incident cohort was 
identified using the SRQ, where all patients with new-onset RA, defined as < 12 month 
with RA symptoms, between 1997 and 2012 were identified. Up to ten general 
population comparators were matched to each RA patient based on birth year and 
area of residency using the TPR.  
5.3.4.3 Follow-up and outcomes 
An index-date, serving as start of follow-up date, was assigned to all study subjects. 
For the prevalent RA patients, the index-date was set to the second visit listing RA and 
their corresponding general population comparator subjects received the same index-
date. For the patients with incident RA and their matched comparators, the index-
date was defined as the date of RA-diagnosis.  
All subjects with a diagnosis of HF prior to the index-date were excluded. Study 
subjects were then followed in the NPR for the outcomes HF overall, ischemic HF and 
nonischemic HF. The different outcome definitions were based on ICD-coding and 
required slightly different exclusion-criteria, censorings during the follow-up and 
actual outcome-definition.  
HF overall was defined as a first ever main diagnosis of HF during the follow-up. 
Ischemic HF was defined as i) a first ever main diagnosis of HF in subjects with a pre-
existing diagnosis of IHD, or ii) a first ever main diagnosis specifically indicating 
ischemic HF. Subjects with incident HF without antedating IHD (nonischemic HF) 
during follow-up were censored. In contrast, nonischemic HF was defined as a first 
ever main diagnosis of HF in subjects free of pre-existing IHD. Subjects with IHD prior 
to the index-date were excluded, and subjects with incident IHD or incident ischemic 
HF during follow-up were censored. Follow-up ended at fulfilment of outcome 
definition, December 31th 2012, death, first migration from Sweden or the any of the 
outcome-specific censoring-criteria. The different outcome definitions are illustrated 
in Figure 5.2.  
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Figure 5.2 Illustration of the different outcome definitions heart failure overall, 
ischemic heart failure and nonischemic heart failure of Study IV. 
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Figure 5.3 Illustration of the different study populations and specific outcomes in 
respective sub-study  
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5.4 STATISTICAL ANALYSES  
5.4.1 Usage of statistics in epidemiological research  
Naturally, the aim of most analytic epidemiological research is to assess the causal 
effect of one exposure (e.g. RA) on one outcome (e.g. HF y/n). Importantly though, 
statistical analyses used in epidemiology describe the relationship between the 
exposure and outcome, but do not necessarily imply a causal relationship between the 
two. Therefore, prior to describing the statistical models applied within the different 
studies of this thesis, the difference between association and causation and strategies 
for getting closer to estimating a true causal effect will be briefly discussed.  
Estimating the true causal effect would require observation of counterfactual 
outcomes. This actually means that, apart from observing the outcome (e.g. HF y/n) 
corresponding to the factual exposure status (e.g. RA), we would also have to observe 
the outcome in the same study subjects in a scenario where they switch exposure 
status (to non-RA) under exactly the same time period.188 Needless to say, this is a 
completely unrealistic scenario, as we can only observe one outcome corresponding to 
the factual exposure status; all counterfactuals outcomes are missing. In the 
epidemiological research setting, we try to overcome this issue by attempting to create 
exchangeability between the exposed (RA) and non-exposed (non-RA) groups. Using 
Study IV, where the RR of HF in RA, was assessed as an example, exchangeability 
would imply that the risk of HF would be exactly the same among the non-RA patients 
as among the RA-patients if they switched exposure-status to RA. The consequence of 
the risk being equal in all groups defined by exposure status is that the risk must be 
equal to the risk under exposure in the whole population. In an ideal randomized 
controlled trial (RCT) where all pre-exposure variables are equally distributed over 
exposure-levels, exchangeability is achieved by design. Hence, association is equal to 
causation in the ideal RCT.189, 190  
Considering that RCTs often are impractical, unethical and unfeasible, we must 
instead rely on observational studies, such as the ones included in this thesis, in 
epidemiological research. Exposed and non-exposed groups included in observational 
studies are not exchangeable. The non-exchangeability is caused by selection bias or 
confounding. Selection bias arises when the association between exposure and 
outcome differs in the study population and the source population and is further 
discussed in the section on methodological considerations. Confounding occurs when 
the exposure and outcome share common causes (confounders), which distort the 
observed association.191 To identify and limit non-exchangeability, all causal and non-
causal paths, linking the different variables (including all potential confounders) 
under study should be identified based on a priori subject matter knowledge about the 
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underlying biological mechanism before deciding on which analytical approach to 
take.192  
Directed acyclic graphs (DAGs) are a graphical approach to identifying and visualizing 
the causal relations between the different variables of interest.193  
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Example of a directed acyclic graph (DAG). X represents the exposure, Y 
the outcome and the directed arrow between them the direct effect of X on Y. 
Alternative pathways exist via confounder U, mediator V and collider Z.  
In Figure 5.4 a basic DAG is provided so as to illustrate the fundamental concepts of 
DAGs. Variables of interest are linked by arrows, stating a causal effect and also the 
direction of the effect, i.e. an arrow pointing from X to Y indicates that variable X 
affects Y. Consider the relationship (path) between X (exposure) and Y (outcome) is 
the association we are interested in estimating. To do so, all other variables linked to X 
and Y creating alternative pathways should be identified, and this is where the DAG is 
truly helpful. Confounders (U) are common causes of exposure and outcomes as 
previously described. Mediators (V) are factors in the causal pathway between the 
exposure and outcome. Colliders (Z) are factors that can arise from both exposure and 
outcome.  
Prior to estimating the effect of X on Y, one has to decide which effect is of interest 
and all ‘back-door’ paths must be identified. Back-door paths are those other than the 
direct path connecting X and Y and these can be opened or closed. In Figure X, the 
back-door paths connecting X and Y via confounders U (X-U-Y) and mediators V (X-
V-Y) are opened. In contrast, the back-door path via collider Z (X-Z-Y) is closed.193 
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When aiming to assess the total effect, neither confounders nor mediators are 
accounted for in the analyses. Aiming to assess the direct effect only requires 
conditioning on both confounders and mediators in the statistical analysis. 
Importantly, conditioning on mediators is not uncomplicated as it can result in 
opening additional paths and thereby introduce bias. The closed back-door path via 
collider Z should generally not be controlled for, since it results in an open path which 
could lead to biases.  
5.4.2 Statistical concepts  
Several factors affect the choice of statistical method, and typically there are a number 
of assumptions, which should be satisfied for the specific statistical method of choice 
to be valid. Firstly, there are different sets of tests depending on whether the 
comparison groups are paired (as, for example, in cross-over design or matched pairs) 
or independent. Secondly, the characteristics (categorical vs. continuous, distribution) 
of the data further affect the choice of statistical method.  
Logistic regression 
Logistic regression is used when the dependent variable is binary (ACS y/n), whereas 
the independent variables can be of any type (categorical or continuous). For instance, 
logistic regression is used to predict the binary outcome in the presence of a particular 
feature. Logistic regression produces Odds ratios (ORs) as effect estimates. In 
unconditional logistic regression, all cases are compared with all controls. In matched 
study-designs, conditional logistic regression is instead used to compare cases with 
their matched controls. When we are interested in the simultaneous relationship 
between the dependent variable and several independent variables, the logistic 
regression can be extended to multiple regression, containing several independent 
variables. Logistic regression models were used to some extent in all of the substudies 
included in this thesis. When it is necessary to adjust for a large number of potential 
confounders (which can lead to diminished power), a propensity score (PS) can be 
calculated based on the chosen variables and used for adjustment (see Box 5.2 for a 
more detailed explanation of propensity score).  
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Box 5.2 Description of propensity score  
Propensity Score  
A propensity score (PS) is defined as the probability (between 0 and 1) of belonging to 
a specific exposure-status (RA y/n) based in selected baseline covariates 
(confounders).194 The PS is commonly calculated using a logistic regression model 
and serves as a balancing score aiming to create exchangeability between exposed and 
non-exposed study groups.195 Several methods can use the PS to create balance 
between exposed and unexposed groups. The PS can be used for matching, 
stratification, inverse probability weighing and covariate adjustment. Adjusting for 
the PS as a covariate allows adjustment for a large number of covariates and 
minimizes loss of information.    
 
Time to event analysis – Cox proportional hazard regression 
Statistical methods used in time to event analyses must be able to deal with censored 
observations during follow-up, which typically arises when the study subject is lost to 
follow-up (e.g. emigrates) or is still alive and has not developed the outcome at the 
end of follow-up. There are also often competing risks, an event other than the 
outcome of interest that prevents the outcome of interest from occurring (e.g. IHD 
during follow-up in Study IV which prevent the outcome nonischemic HF), to take 
into account, by for example censoring. The Cox Proportional Hazard model, which is 
commonly used in time to event analysis, estimates the effect of specific exposures, 
which can be time-dependent, on the event of interest. Hazard ratios (HRs) are the 
effect estimate produced by Cox regression models and gives an estimate of the 
probability of the event occurring in a given time period when comparing two groups. 
Importantly, the assumption of proportional hazards, meaning that HR of the two 
compared groups should remain constant over time, must be satisfied for the Cox 
regression model to be considered a valid method. The proportional hazard 
assumption is tested by, for example, visually inspecting survival or cumulative 
incidence curves or by introducing an interaction term in the statistical model.   
5.4.3 Study I  
In Study I, the association between each exposure of interest (Table 5.2) and the 
outcome ACS in RA was assessed using conditional logistic regression models. For the 
disease activity exposures, for which there were several reported values during the 
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follow-up, area under the curve (AUC) measurements were calculated by taking the 
average of all reported values during the different time periods under study. For 
inclusion in the AUC-analysis, at least two reported values were required, and for 
inclusion in a follow-up period of two or three years at least one value each year was 
required. Only values up until the outcome were included. AUC values were assessed 
as overall means and also by further categorizing them into tertiles or into predefined 
threshold values (comparing high values with lowest/normal as a reference). Crude 
ORs were estimated using conditional logistic regression models, taking the 
individual-matching design into account and adjusted for a linear effect as well as a 
quadratic effect of age. To minimize the impact of other potential confounders and/or 
mediators, a multivariate logistic regression model of AUC measurements was further 
adjusted for smoking, high BMI, history of MI and sick leave during the first year 
following RA-onset. Furthermore, analyses were also stratified by history of ACS 
and/or CV risk factors.  
5.4.4 Studies II & III 
In Study II, clinical ACS characteristics were compared between RA- and non-RA 
patients with ACS, and the variables of interest included both dichotomous and 
continuous variables with different distributions. In Study III, filled prescriptions of 
gold standard secondary preventive drugs (dichotomous) were compared among the 
same study subjects. Differences in dichotomous variables and normally distributed 
continuous variables were assessed using logistic regression models adjusted for age 
and sex so as to obtain a two-tailed p-value. For ordinal or non-normally distributed 
continuous variables, the Mann-Whitney U test was used to obtain a two-tailed p-
value. A p-value < 0.05 was considered significant.  
The Kaplan-Meier method was used to analyse all-cause mortality in Studies II and 
III. The relative risk of all-cause and cause-specific death, and recurrent events among 
RA-patients compared to non-RA patients with ACS was analysed using Cox 
regression models. The models were stepwise adjusted to account for all known 
accessible confounders and/or mediators. The crude model was adjusted for age and 
sex. RA is, as described in the background section, associated with several comorbid 
conditions which in the present analysis could be considered mediators between RA 
and mortality/recurrence. The second model was, therefore, adjusted for a propensity 
score (PS) including age, sex and educational level as potential confounders in terms 
of comorbid conditions and/or pharmacotherapies (used as proxies for these 
conditions) up until 90 days prior to baseline. The results from Study II suggest that 
RA is associated with a more severe clinical ACS phenotype, why ACS type could also 
be considered a mediator (a more severe ACS is associated with poorer outcomes 
compared to milder ACS types) between RA and, in particular short-term, mortality. 
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Therefore, the third model was, in addition to the PS, also adjusted for ACS type. 
Finally, inadequate usage of secondary preventive drugs (as assessed in Study III) 
after ACS is known to be associated with poorer long-term outcomes. Different usage 
of these drugs in RA-patients compared to non-RA patients could, therefore, mediate 
an observed association between RA and long-term mortality/recurrence following 
ACS. Since filled prescriptions of secondary preventive drugs were assessed in study 
subjects alive during the entire time period under study, adjusting for filled 
prescriptions would introduce bias. Analyses of long-term mortality and recurrence 
were instead stratified into subgroups including subjects fulfilling a combination of at 
least three secondary preventive drugs during i) the first time period after ACS for one 
year analysis, and ii) at least two time periods for the complete follow-up period 
(Figure 5.5).  
 
 
Figure 5.5. Directed acyclic graph illustrating the confounders and mediators adjusted 
and/or stratified for in analyses of Study II and Study III. Model 1 adjusted for 
demographics; Model 2 adjusted for demographics and comorbidities; Model 3 
adjusted for demographics, comorbidities and ACS-type; Model 4 stratified on the 
number of filled prescriptions of secondary preventive drugs.  
5.4.5 Study IV 
In Study IV, where the RR of HF types was assessed, a logistic regression model 
adjusted for age and sex was used to estimate ORs as a measurement of the RR of HF 
prior to the start of follow-up among the incident RA patients compared with the 
controls. Cox regression models were used to calculate HRs as a measure of the 
association between RA and the different HF outcomes after the start of follow-up. 
Crude HRs were calculated with time since the index-date as time-scale and adjusted 
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for sex, age at the index-date and residential area. For analyses of the prevalent RA 
cohort with corresponding controls, the model was further adjusted for educational 
level and CV comorbidities and/or treatments at baseline (hypertension, IHD, 
diabetes type 1 or 2, chronic obstructive pulmonary disease, heart valve disease or 
surgery, atrial fibrillation, renal failure, alcohol-related conditions, usage of nitro-
glycerine, warfarin, acetylsalicylic acid, calcium antagonists, diuretic agents, RAS-
blocking agents, beta-blockers, lipid-lowering agents, insulin and oral antidiabetic 
agents). Analyses were stratified on sex and RF-status at baseline, and among patients 
with new-onset RA and their comparators, analyses were stratified within time periods 
since RA-diagnosis to assess the impact of RA duration. The impact of RA disease 
characteristics on the short-term RR of HF was also assessed among the patients with 
new-onset RA. A series of sensitivity analyses were performed.  
All analyses included in the studies of this thesis were carried out with SAS version 9.3.  
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6 ETHICAL CONSIDERATIONS 
All researchers conducting medical research involving human study subjects are 
responsible for protecting the study subjects from the potential harm and discomfort 
their involvement might cause.  
The Declaration of Helsinki, an international agreement developed by the World 
Medical Association, contains ethical guidelines for the protection of human subjects 
included in medical research and serves as an ethical compass for international 
researchers.196 According to these guidelines, a detailed research protocol including 
ethical considerations must be carefully evaluated and approved by a research 
committee prior to commencing the research. In Sweden, this process is regulated in 
the Act of Ethical Review197 and there is one central and six regional ethical review 
boards responsible for this process.  
It is specified in the Act of Ethical Review that research without informed consent, but 
of course it applies to all medical research and should only be conducted if results 
could be beneficial for the study subject or for others with the same condition. The 
aim of the studies included in this thesis is that the result will contribute to increased 
knowledge about the association between RA and specific CVDs and their outcomes, 
which could partly be implemented into clinical routine care and thereby be beneficial 
for patients with RA.  
Informed consent constitutes one of the foundations of the ethical principles 
concerning all medical research including human subjects. Generally speaking, with 
few exceptions, each potential study subject should, prior to forming an opinion on 
whether to give consent for study-participation, receive sufficient and structured 
information, adapted to be easily understood. Larger register-based studies, such as 
the ones included in this thesis, constitute one of the exceptions to informed consent. 
The data used has already been collected and it would not be possible to collect 
informed consent from the, usually, large number of study subjects included.  
Study I included data partly collected from the medical charts of all of the study 
subjects. Informed consent was not collected from the study subjects prior to 
retrieving the medical records, but each head of clinic was informed and asked for 
permission. All study subjects were already included in the EIRA study and had upon 
inclusion in EIRA also given their consent to information being collected from their 
medical charts. We argued that requesting another informed consent from these study 
subjects might result in yet more privacy-intrusion, due to having to find out more 
information on each study subject and also by risking causing concern by informing 
them about the study aims. Thus, we assessed that the risk of causing the study 
subjects discomfort would overweight the potential benefit from informing them. 
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Data used in Studies II–IV included anonymized data from population-based health 
registers and quality of care registers, and informed consent was not requested.  
Another key element of ethical considerations in medical research is prevention of 
violation of personal integrity, which is regulated in the Personal Data Act.198 The 
privacy of the study subjects must be protected and sensitive individual information 
should be handled with care in accordance with the act. The PIN from the data used 
in Studies II–IV had been replaced with an anonymous study participant number by 
the NBHW upon delivering of the data. In Study I, the PIN was replaced with an 
anonymous study participant number when collecting the data. All data used are 
stored in secure servers available only to researchers involved in the specific project 
through password-protected computers. Due to the format of the data used in all 
studies in combination with the storage and handling of the data, the risk of 
identifying specific individuals and violation of privacy was regarded as minor.  
All studies included in this thesis were approved by the Ethical Review Board 
Stockholm, Sweden.  
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7 MAIN RESULTS 
7.1 RISK FACTORS FOR ACUTE CORONARY SYNDROME IN NEW-ONSET 
RA (STUDY I)  
The 138 cases and 624 matched controls included in Study I were followed for a 
median duration of 4.8 years (range 0.4–11). Half of the events occurred within the first 
five years following RA-onset. Of the traditional CV risk factors, smoking, BMI and a 
history and CVD was associated with ACS risk. Neither usage of corticosteroids nor 
DMARDs within the first 60 days following RA-diagnosis were associated with an 
increased ACS risk.  
Measurements of high disease activity compared to lower were generally associated 
with an increased risk of ACS both during the first year and during the complete 
follow-up period (Figure 7.1). High disease activity measured using DAS28 was 
associated with a three-fold ACS-risk compared to low disease activity. Out of the 
DAS28-components, high ESR and high general health were associated with a three-
fold and 2.5-fold ACS-risk during the first year of follow-up. Among other DAS28-
components there was also an association or borderline significant association 
between high markers compared with lower.  
 
Figure 7.1 Forrest plot of the relative risk of ACS for measurements of disease activity 
during the first year following RA-onset and the complete follow-up period. Highest 
tertile compared to lowest. Odds ratios with 95% confidence intervals. CRP, C-reactive 
protein; ESR, erythrocyte sedimentation rate; GH, general health; TJC, Tender joint 
count; SJC, swollen joint count  
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ORs of DAS28, ESR and GH remained significantly increased after adjusting analyses 
of CV risk factors and history of MI and also in a subset of the population where 
subjects with a history of CVD were excluded.  
Shared epitope, one or two alleles, was not associated with any increased ACS risk. 
Approximately two-thirds of both cases and controls were RF- and/or ACPA-positive. 
There was no association between RF-positivity and risk of ACS, whereas ACPA-
positivity and in particular high positive ACPA was borderline significant associated 
with ACS-risk (Figure 7.2) 
 
Figure 7.2 Forrest plot of the relative risk of ACS for autoantibodies. Odds ratios with 
95% Confidence intervals. ACPA, Antibodies towards citrullinated peptides; RF, 
Rheumatoid factor.  
Please see Paper I and corresponding Supplementary information for the complete 
results.  
 
7.2 CLINICAL ACS CHARACTERISTICS (STUDY II)  
A total of 743 (65%) of the RA patients with ACS and 2203 (69%) of the non-RA 
patients with ACS were included in RIKS-HIA and analysed regarding clinical ACS 
parameters. Of the subjects included in RIKS-HIA, RA patients and non-RA patients 
did not differ regarding presenting symptoms. However, during the same period in 
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which study subjects were identified in the NPR, another 243 (0.20%) of the RA 
patients vs. 785 (0.13%) of the non-RA subjects died from ACS or sudden cardiac death 
out of hospital (and were not registered in the NPR with incident ACS). In RIKS-HIA, 
RA patients showed several signs of experiencing a more severe ACS compared to the 
non-RA patients. The RA patients more often presented with STEMI, poorer Killip-
class and had higher troponin-levels compared to non-RA patients. Out of the patients 
with STEMIs, RA patients more often received primary reperfusion treatment. The RA 
patients also suffered from higher frequencies of in-hospital complications, such as 
received treatment with IV diuretics and inotropic agents, going into cardiogenic 
shock and dying in-hospital, compared to non-RA patients (Table 7.1).  
Table 7.1 Clinical presentation, in-hospital treatment and complications in RA 
patients and non-RA patients with ACS.  
 RA patients  
(%) 
Non-RA 
patients (%) 
P-value 
AT ADMISSION  
ECG    
   LBBB 4.8 5.6 0.44 
   ST-Elevation  35.3 30.5 0.001 
   ST-Depression 19.8 22.4 0.16 
Killip-Class   0.01 
   1 83.3 87.1  
   2 12.8 9.6  
   3 2.5 2.3  
   4 1.5 1.0  
Troponin, tertiles   0.0001 
   1 27.5 35.3  
   2 34.7 32.8  
   3  37.8 31.8  
TREATMENT AMONG SUBJECTS WITH STEMI 
    Any reperfusion  74.1 66.2 0.01 
    PCI 62.3 54.4 0.02 
IN-HOSPITAL COMPLICATIONS    
   Treatment IV. Diuretics 25.3 20.9 0.02 
   Treatment IV. Inotropic agent  4.6 2.5 0.04 
   Cardiogenic shock 3.6 2.2 0.04 
   In-hospital death  6.1 4.1 0.04 
DISCHARGE DIAGNOSIS 
   STEMI 42.0 37.4 0.04 
   NSTEMI  58.0 62.6 0.04 
Please see Paper II and corresponding Supplementary information for the complete 
results in clinical characteristics in ACS.  
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7.3 MORTALITY AND RECURRENCE AFTER ACS (STUDY II AND III)  
Both short-term and long-term mortality as well as recurrence were increased among 
RA patients with ACS compared to the non-RA patients with ACS (Figure 7.3).  
 
 
Figure 7.3 Failure function of recurrent ACS (above) and overall Kaplan-Meier survival 
(below) in patients with RA and general population comparators with incident ACS 
between 2007 and 2010.  
RA patients with ACS suffered an approximately 60% increased all-cause mortality 
risk within the first week as well as the first month following the ACS. A majority of all 
deaths among both RA- and non-RA patients were related to cardiac mortality, and 
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the risk of cause-specific mortality was similar to all-cause mortality. The mortality 
risk remained increased with 60% during a follow-up of 1 year and increased to 70% 
during the complete follow-up period. The risk of recurrent ACS was increased by 
approximately 30% both during a follow-up of 1 year and during the complete follow-
up period. Adjusting analyses using the propensity score, based on all accessible 
confounders, only reduced the HRs slightly, but they all remained significantly 
increased (Figure 7.4).  
 
Figure 7.4 The relative mortality and recurrence risk among RA-patients with ACS 
compared with non-RA patients with ACS during the different time periods.  
Please see Papers II and III with corresponding Supplementary information for the 
complete results on mortality and recurrence.  
 
7.4 SECONDARY PREVENTION (STUDY III)  
Figure 7.5 shows the proportion of RA patients with ACS and non-RA patients with 
ACS filling prescriptions of each drug during the four consecutive time periods 
following ACS. When analysing prescription pattern after any type of ACS, patients 
with RA filled significantly fewer prescriptions for antiplatelets, statins and RAS-
blocking agents during several of the time periods (figure 7.5).  
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Figure 7.5 Proportions of dispensed prescriptions of secondary preventive drugs 
during 4 consecutive time periods following any ACS in patients with RA (solid line) 
and non-RA patients (dotted line).  
After stratifying the result on type of ACS, based on ICD-codes registered in the NPR, 
a majority of observed differences disappeared. Among patients registered with 
transmural MI, there were virtually no remaining significant differences. (Figure 7.6) 
shows filled prescriptions of the different drugs in patients with transmural MI).  
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Figure 7.6 Proportions of dispensed prescriptions of secondary preventive drugs 
during 4 consecutive time periods following transmural infarction in patients with 
RA (solid line) and non-RA patients (dotted line).  
Please see Paper II with corresponding Supplementary information for the full results 
on secondary prevention after ACS.  
 
7.5 THE RELATIVE RISK OF HEART FAILURE IN RA (STUDY IV)  
The relative risk of HF in prevalent RA  
The prevalent RA patients had higher incidence rates of all HF subtypes compared to 
their matched general population comparators. The incidence rate of HF overall was 6 
per 1,000 person-years among RA patients compared with 3 per 1,000 person-years 
among their comparators, corresponding to an approximately 70% increased risk of 
HF overall (Figure 7.7). Similarly, 3.5 and 2.7 per 1,000 person-years among prevalent 
RA patients developed nonischemic and ischemic HF respectively (compared to 1.9 
and 1.4 per 1,000 person-years among comparators). The prevalent RA patients 
suffered an approximately 70% increased risk of nonischemic HF and a 90% increased 
risk of ischemic HF. Adjusting for confounders in term of pharmacotherapies and 
comorbidities at baseline only reduced HRs slightly (Figure 7.7).  
 52 
 
Figure 7.7 Forrest plot of the relative risk of heart failure by subtype in subjects with 
prevalent RA compared with general population comparators. Hazard ratios with 95% 
CI.  
 
The relative risk of HF by RA duration  
A history of all subtypes of HF prior to RA-onset was equally common among the 
patients with new-onset RA compared to their general population comparators. 
Stratifying the RR of HF within time periods after RA-onset revealed an increased RR 
of all subtypes already in the first year following RA-onset. Within the first year 
following RA-onset, there was an approximately two-fold increased relative risk of 
nonischemic HF and a 1.5-fold increased relative risk of ischemic HF. The RR of 
Nonischemic HF seemed to decline over time after RA-onset whereas the RR of 
ischemic HF on the other hand increased (Figure 7.8).  
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Figure 7.8 Forrest plot of the relative risk of heart failure in patients with RA 
compared with general population comparators in time-periods after RA-onset  
 
Risk factors for HF in RA  
High mean DAS28 and ESR during the first year following RA onset was associated 
with an increased risk for all subtypes of HF, but most pronounced for nonischemic 
HF. Similarly, high CRP and usage of corticosteroids within the last 3 months prior to 
the HF was associated with an increased risk of nonischemic HF, whereas there was 
no effect on ischemic HF (Table 5.4). 
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Table 7.2 The impact of various RA disease factors on the risk of incident heart failure 
within 1 year after RA-onset in patients with new-onset RA. Hazard ratios adjusted for 
age and sex.  
 HF OVERALL 
HR (95% CI) 
ISCHEMIC HF 
HR (95% CI) 
NONISCHEMIC 
HR (95% CI) 
All  1.75 (1.40-2.19) 1.49 (1.05-2.12) 2.04 (1.52-2.73) 
Mean values:    
ESR ≥ 40 vs. <40 2.80 (1.78-4.42) 2.41 (1.15-5.08) 3.03 (1.69-2.73) 
CRP ≥30 vs. < 30 1.72 (1.08-2.74) 0.90 (0.39-2.09) 2.40 (1.36-4.24) 
GH ≥60 vs. <60 1.95 (1.20-3.15) 1.56 (0.69-3.52) 2.45 (1.32-4.52) 
DAS28 ≥5.2 vs <5.1 2.93 (1.83-4.69) 2.68 (1.24-5.78) 3.35 (1.84-6.09) 
HAQ ≥1.0 vs. <1.0 2.09 (1.32-3.31) 2.59 (1.26-5.25) 1.70 (0.94-3.08) 
Corticosteroids 0.96 (0.53-1.74) 0.39 (0.15-1.02) 3.12 (1.30-7.44) 
Biologic drugs  0.80 (0.32-2.03) 0.81 (0.19-3.55) 0.41 (0.12-1.42) 
ESR, Erythrocyte sedimentation rate; CRP, c-reactive protein; GH, general health; DAS28, 
disease activity score; HAQ, health assessment questionnaire 
 
Please see Paper IV with corresponding Supplementary information for the complete 
results on association between RA and HF.  
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8 DISCUSSION 
8.1 METHODOLOGICAL CONSIDERATIONS 
The aim of observational studies is, of course, to present accurate effect measurements 
of the association studied. Observational studies are, however, prone to include a 
certain set of weaknesses, which are important to be aware of when planning, 
conducting and interpreting the results. The validity of the study is categorized into 
internal validity and external validity. Internal validity involves factors related to the 
study populations’ representativeness. High internal validity implies that the observed 
association is similar to the actual association of the source population. External 
validity is also referred to as generalizability, and reflects whether the results can be 
transferred to populations other than the one under study. The precision (random 
error) refers to data variability due to chance. The accuracy of the study is determined 
by the validity in combination with the precision.     
8.1.1 Internal validity  
The internal validity is affected by systematic (or non-random) errors and random 
errors.  
8.1.1.1 Systematic error 
The classic systematic biases affecting the internal validity are categorized into 
selection bias, information bias and confounding. The impact of these biases is, in 
contrast to random error, not affected by sample size.  
Selection bias  
As the name implies, selection bias is occurs in the process of selecting the study 
population and is defined as a different association between exposure and outcome 
among the study population compared with the source population. For instance, 
sampling a study population from a specific hospital setting or register source, which 
tends to include or hospitalize subjects with severe disease, would lead to a study 
population including subjects with overall a more severe disease in comparison with 
the source population. Selection bias leads to under- or overestimation of the 
measurement of the true association and would, if there is an association between 
disease activity and the outcome, lead to an overestimation of the true effect, which in 
turn affects the internal validity of the study. Selection bias and confounding often 
overlap, and selection bias can sometimes be dealt with as confounding.  
Using population-based cohorts, as in Studies II-IV, reduces the risk of introducing 
selection bias. In these studies, the NPR was used to identify cohorts of patients with 
prevalent (established) RA. In Study IV we included an additional study population of 
 56 
patients with incident RA. The incident RA cohort was identified using the SRQ, 
which, as previously described, includes patients diagnosed and entered by 
rheumatologists. The entering of patients in such registers (and thereby their 
coverage) might be affected by the underlying health status of the patient as well as 
the disease characteristics. Patients with a poorer health status and a short expected 
survival time might not be included, which would lead to a healthier RA-population in 
SRQ compared with the source population. This might distort the comparison of the 
RA group to the population group.  
In Study I the population was identified within the EIRA study where RA patients, 
similarly with SRQ, are included by rheumatologists from certain centres which could 
affect the internal validity of the study. The participation rate in EIRA is, however, 
high and previous investigation of non-participation demonstrated that non-
participation among cases (which the study cohorts were sampled from) was 
associated with lower socioeconomic status.199Since low socioeconomic status is 
associated with an increased risk of ACS, some degree of selection bias leading to an 
underestimation of the true effect is possible.  
One specific type of selection bias referred to as informative censoring could pose a 
limitation in Study IV. Informative censoring occurs in cohort studies when there is a 
differential loss of follow-up or censoring between an exposed and non-exposed 
group. In the analysis in which we assessed the RR of nonischemic HF, we censored 
subjects who developed IHD during the follow-up period. Since RA is associated with 
an increased risk of IHD, a higher proportion of RA patients were presumably 
censored due to IHD during follow-up. Potentially, the subjects developing IHD are 
also at increased risk of developing nonischemic HF, which in would lead to an 
underestimation of the RR of non-ischemic HF among the RA patients.  
Information bias  
Inaccurate collection of study variables leads to biased information, which is referred 
to as misclassification. Misclassification is categorized into differential and non-
differential. When misclassification is equal among exposed and unexposed, it is non-
differential the measure of the association is typically not affected. In contrast, 
differential misclassification differs depending on exposure status. Recall bias refers to 
the differential misclassification caused by the tendency of exposed study subjects to 
report information differently compared with non-exposed study subjects. Surveillance 
bias refers to another specific type of differential misclassification, in which the 
outcome differs among exposed subjects due to more intense or frequent surveillance 
compared with non-exposed subjects.  
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In Study I some of the information on potential risk factors was collected from the 
questionnaires used in the EIRA study. The information was, however, collected 
before the outcome of Study I (ACS) and analyses pertained to baseline in the 
analyses, which minimizes the risk of recall bias. Both cases and controls in Study I 
were subjects with RA, which is why differential misclassification of the outcome by 
RA status is not an issue. Furthermore, the ACS-diagnoses were validated within the 
study.  
In Study IV, the outcome was HF. The more intense and frequent health care contact 
among RA patients could potentially introduce a surveillance bias. We did, however, 
use main diagnosis only, which is known to have a high validity.  
Other information included in the studies was collected from nationwide registers 
where it has been prospectively collected and with almost complete coverage, which 
prevents misclassification to occur.  
Confounding 
The concept of confounding was introduced in section 5.4.1. To repeat, confounding 
refers to the presence of common causes (confounders) of exposure and outcome, 
which might distort the observed association. Confounders should be identified based 
on a priori subject matter knowledge, which can be illustrated using DAGs as 
previously described. The issue with confounding can be overcome by restriction. 
matching, stratification or adjusting.  
In Study I, age, sex and year of RA diagnosis were considered to be confounders. 
Cases and controls were matched based on sex and year of RA diagnosis, and analyses 
were adjusted for age. Confounding in Studies II and III is illustrated in the DAG in 
figure 5.5. Age, sex, educational level, CV risk factors and CVD are associated with ACS 
and also affect the outcome after ACS, why analyses were adjusted for these factors in 
a first and second step. Furthermore, the type or severity of ACS affects in mortality 
and recurrent events. Since the patients with RA suffered from more severe ACS 
compared to non-RA patients, we adjusted for ACS-type in a third step to assess the 
influence of the higher frequency of more severe ACS among RA-patients. In Study 
IV, we considered age, sex and area of residency confounders and matched the RA-
subjects to general population comparators based on these factors. Additionally, we 
considered educational level and a number of CVDs and other diseases (or 
pharmacotherapies used as proxies for these diseases) confounders due to a known 
association with RA and HF and adjusted for these in a multivariate model.  
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8.1.1.2 Random error 
Random error refers to the variability of the data due to by chance. The precision 
can be improved by increasing the sample size. To measure the variability of the data 
and to derive the measurements from the study population to the source population 
statistical methods are used. The P-value is used for hypothesis testing and 
confidence intervals are used for estimation of the data variability. If the p-value is 
less than or equal to the probability level α, which almost always is arbitrarily set to 
0.05 (the risk of incorrect rejection of null hypothesis is less than 5%), the null 
hypothesis is rejected (i.e. the result is statistically significant). In contrast, a p-value 
greater than α does not reject the null hypothesis (the result is not statistically 
significant). Importantly, statistical significance does not necessarily transfer into 
clinical significance, and the results should be interpreted in relation to other 
aspects such as a plausible biological hypothesis and presence of systematic errors. 
Confidence intervals are used to describe the statistical variation underlying the 
point estimate. The level of confidence is usually set to 95%, meaning that, if data 
collection and analysis were to be repeated a number of times, the interval would 
include the correct value 95% of the time. The P-value and confidence intervals, 
which are based on the same equation, are related. If the 95% CI include the null 
hypothesis value (1 if using relative risks), the p-value will not be greater than 0.05 
and thus indicate non-statistical significance.   
We used confidence intervals as an estimation of the precision around the point 
estimates in all studies. In some of the analyses in Study I where the number of 
observations was smaller, the CIs are hence wider, which is why the result of these 
specific analyses should be interpreted with care. In the other studies, CIs were 
narrow (with a few exceptions) indicating that there was enough power to detect 
differences between exposed and non-exposed group. In Studies II and III we used 
p-values to determine whether statistically significant differences in clinical ACS 
characteristics and usage of secondary preventive drugs.  
8.1.2 External validity  
External validity refers to the generalizability of the study, i.e. how well the study 
results can be applied to study settings and populations other than those included in 
the study. In Study II- IV we included prevalent RA-cohorts based on the NPR. 
Selecting subjects fulfilling a definition for prevalent RA and thereby excluding 
subjects with incident RA, might affect the external validity. There are several 
potential differences in disease characteristics, such as treatment, level of or 
accumulated inflammatory activity, physical impairment etc. among prevalent 
compared with incident RA. Therefore, the results might not be readily transferred to 
patients with new-onset RA. In Study II, RIKS-HIA was used to characterize the ACS 
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phenotype in a subset of the study population. Information in RIKS-HIA is based on 
admissions to coronary intensive care units. In some areas, inclusion in RIKS-HIA is 
not indicated in patients above 80 years of age, which is why many elderly RA and 
non-RA subjects were not included in this specific analysis. The coverage was similar 
for both RA- and non-RA patients, which is why the results were not biased in any 
direction, but the generalizability to RA patients with ACS above 80 may be limited. In 
Study I, we identified cases and controls from EIRA. EIRA has an upper age limit of 
70, which limits the generalizability to older age groups.  
All studies were based on a Swedish RA population and conducted in the Swedish 
health care system, which might to some degree affect the generalizability to other 
populations and settings.  
 
8.2 FINDINGS AND IMPLICATIONS 
In this thesis, results regarding potential risk factor for ACS, clinical ACS 
characteristics, prognosis and usage of secondary preventive drugs after ACS as well as 
risk of and risk factors for HF in RA have been reported.  
8.2.1 Risk factors for ACS in RA 
The main finding of Study I was an association between markers of high 
inflammatory activity and disease activity, in particular during the first year following 
RA-onset, and an increased risk of ACS. Out of the CV risk factors, high BMI, a 
medical history of MI and previous smoking were also associated with an increased 
risk of ACS. The impact of these factors could however not explain the increased risk 
of ACS caused by high inflammatory and disease activity. Rheumatoid factor-positivity 
was not associated with ACS-risk, whereas ACPA-positivity and in particular high 
levels of ACPA was associated with an increased risk of ACS. Treatment with DMARDs 
or corticosteroids was not associated with ACS-risk.  
Similarly with our results, previous studies have reported an association between high 
inflammatory activity and disease activity and risk of CVD in RA.128, 130-137 Since results 
based on studies using a composite CVD outcome can be difficult to translate into 
specific conditions and clinical practice, we instead focused on clinically significant 
ACS in our study. Additionally, we used a contemporary RA-cohort where we could 
access information exposures of interest from RA-onset.  
The involvement of inflammation in the development of atherosclerosis is well 
established and inflammatory activity has been shown to affect the extent and 
composition of atherosclerotic lesions.81 In fact, the pathophysiology of 
atherosclerosis, which is currently considered a chronic inflammatory disease, share 
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many features with the pathophysiology of RA.83, 84 The inflammatory process of both 
atherosclerosis and synovial inflammation is characterized by endothelial activation 
and subsequent expression of adhesion molecules followed by infiltration of various 
types of leukocytes and other immune cells. Many of these immunological responses 
in RA are also seen in patients with ACS. For example, specific subsets of CD4+ T-cells, 
described to be involved in the pathogenesis of RA, have also been detected in blood-
samples from patients with ACS.  The characteristics of this specific subset of T-cells 
have been observed to be similar in patients with RA200 and patients with ACS201 as an 
indication of a similar autoimmune response. Our results suggest that a high mean 
inflammatory activity soon after RA-onset is associated with an increased risk of ACS. 
The development of atherosclerotic lesions occurs over several years. Since the high 
inflammatory activity seem to affect the development of ACS within a relatively short 
time-period, the risk increase might be caused by the destabilization of atherosclerotic 
plaques within the coronary arteries. It has been proposed that the T-cells contribute 
to destabilization of atherosclerotic plaques.169, 202 Furthermore, data from post 
mortem126 and coronary CT angiography127 indicates that patients with RA have a 
higher frequency of vulnerable plaques.  
ACPA-positivity and in particular high positive ACPA-levels was also associated with 
an increased ACS-risk in our study. ACPA has previously been associated with an 
increased risk of CVD in both the general population92 and an increased risk of IHD in 
patients with RA.140 In the later study, the association between ACPAs and IHD 
remained after adjusting for ESR, RF-positivity and treatments. There is not an 
established exact role for ACPAs in the pathogenesis of CVD in RA, but ACPAs have  
been associated with subclinical manifestations of CVD, such as more extensive 
atherosclerotic lesions, in RA.141 Furthermore, specific ACPAs have been associated 
with endothelial dysfunction and overall atherosclerotic burden.142  
In contrast to several previous reports, RF-positivity was not associated with an 
increased risk of ACS in our study. The specificity of RF is not as high as the specificity 
of ACPAs,203 which is the currently recommended biomarker to use in the evaluation 
of RA. Rheumatoid factor has been associated with an increased risk of CVD in the 
general population,88-90 but there is no established mechanism for this association. RF 
is also found in other autoimmune conditions, infectious diseases, in smokers, and 
healthy subjects, in particular among elderly individuals. Rheumatoid factor-positivity 
in RA is also associated with a more severe clinical prognosis. The observed 
association between RF and CVD in the general population might be caused by other 
factors related to RF and CVD (confounders). The previously described association 
between RF and CVD in RA could reflect the impact of severe disease related to RF-
positivity rather than a direct association between RF and CVD. In fact, in one study 
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based on 2 cohorts of RA patients from different time periods, there was an 
association between RF and CVD in the older cohort, whereas no association could be 
detected in the more recent cohort.101 Perhaps, the more modern treatment regimes 
available for the patients of the more recent cohort effectively altered and improved 
the inflammatory and disease activity of these patients.  
The rapid risk increase of ACS after RA-onset, the observed association between RA-
related inflammation in relation to RA-onset and the risk of ACS and the impact of 
ACPAs on the ACS-risk in RA suggest that RA-related factors are indeed involved in 
the development of ACS. In support, usage of methotrexate has been associated with a 
decreased risk of CVD in RA. However, the exact mechanism of ACS-development in 
RA remains to be determined.  
Our results underline the importance of a rapid clinical evaluation in patients with 
suspect RA to identify those with RA. Early treatment-initiation and lowering of 
inflammatory activity might decrease the risk of developing ACS. In addition, patients 
with a sustained high inflammatory and disease activity should be extra carefully 
monitored regarding risk factors and symptoms of CAD.    
8.2.2 Clinical characteristics of ACS in RA 
In Study II, we observed more severe ACS characteristics among the patients with 
established RA and ACS compared with the non-RA patients with ACS. In contrast, 
most previous studies investigating the clinical characteristics of ACS in RA have not 
observed any difference. The small number of study subjects included in these studies, 
have however affected the statistical precision and they did not have access to equally 
detailed information on the clinical event as we did in our study. Furthermore, the RA 
characteristics differ between studies, which might also lead to different results.  
The RA-patients in our study more often suffered from STEMIs, showed signs of more 
severe ACS and more often developed in-hospital complications. Of the patients with 
STEMIs, the RA-patients were more often treated with primary reperfusion treatment 
and received primary PCI. These results indicates that the ACS phenotype differ in 
patients with RA compared with non-RA patients. Previous reports have observed an 
increased risk of sudden cardiac death in patients with RA,107 which support this 
observation. Inflammatory activity in non-RA patients has been associated with more 
severe ACS characteristics and a predisposition towards MI rather than UA.96  
Since the pathophysiological mechanism of STEMIs and sudden cardiac death 
typically are caused by total or near total occlusion of a coronary artery caused by a 
thrombus this further supports the impact of RA-related factors on existing 
atherosclerotic lesions by making them unstable and prone to rupture. Inflammation 
 62 
does not only affect the atherosclerotic lesion locally, but also affects the fluid phase of 
blood by promoting thrombus accumulation by increased thrombogenicity and 
impaired fibrinolysis.169 Moreover, inflammation has been associated with impaired 
development of coronary collateral circulation in chronic CAD,204 which could lead to 
larger infarct size due to insufficient blood supply at the time of occlusion.   
The finding of a more severe ACS phenotype in patients with RA, emphasize the 
importance of recognizing this group of patients when assessing and identifying high 
risk ACS patients in clinical practice.  
8.2.3 Outcomes after ACS in RA 
In Study II, we in addition to clinical ACS characteristics also assessed short-term 
mortality, which was significantly increased among RA patients compared with non-
RA patients, which has also been reported in one previous study. In contrast, two 
other studies on short-term mortality after ACS in RA could not detect a difference. 
The increased mortality risk in our study remained after adjusting for a large number 
of potential confounders. Further adjusting for type of ACS decreased the short-term 
mortality risk, which supports the impact of the ACS severity, but could not fully 
explain the overall short-term survival. In Study III, we extended the follow-up period 
and assessed long-term mortality and also risk of recurrent events. Similarly with 
short-term outcomes, the long-term mortality and recurrence risks were also 
increased among RA-patients compared with the non-RA patients. Consistent with 
our findings, a few previous studies have reported an impaired long-term prognosis 
after ACS in RA. Adjusting for comorbidities and ACS-type decreased the RRs slightly, 
but they remained significantly increased.  
Since the more severe ACS-phenotype in RA does not explain the impaired mortality 
and recurrence, other factors are likely to be involved. Several inflammatory 
biomarkers, including hsCRP, have been associated with more severe outcomes 
following ACS in the general population.96 The mechanisms behind these observations 
are not understood, but the inflammatory effect on the atherosclerotic lesions and 
coagulation system has been proposed as an important factor. Furthermore, certain 
inflammatory cells have been shown to affect the electric conduction of the heart, 
which might predispose for arrhythmias, such as ventricular fibrillation, after ACS.205  
8.2.4 Follow-up care after ACS in RA 
Suboptimal usage of secondary preventive drugs after ACS has been linked to adverse 
outcomes, such as mortality and recurrence, in the general population. The observed 
impaired long-term prognosis after ACS in patients, which could therefore potentially 
be explained by a suboptimal usage of these drugs in this patient group. Therefore, we 
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also, in addition to mortality and recurrence, aimed at assessing the usage of 
secondary preventive drugs in Study III. We found that, when conditioning our 
analyses on type of ACS, the usage of secondary preventive drugs was not consistently 
lower among the patients with RA compared to the non-RA patients. One previous 
study has reported on lower in-hospital initiation of certain secondary preventive 
drugs in patients with RA, whereas another study could not detect a difference. Since 
these studies only assessed in-hospital initiation of the drugs it is difficult comparing 
them with our results. In another large population-based study, a lower initiation and 
adherence of aspirin, beta-blockers and statins were observed in patients with RA and 
ACS compared with non-RA patients and ACS. The different results might be 
explained by variations in geographic region and clinical setting, but there were also 
major differences in study design and analytic approaches used. Importantly, we 
stratified the analyses by type of ACS and among patients with transmural infarction 
(which is likely to be translated into STEMI), there were virtually no differences in 
filled prescriptions of any drugs among RA-patients and non-RA patients. As the first 
study, we assessed long-term outcomes and usage of secondary preventive drugs in 
the same cohorts and also attempted to evaluate the impact of drug-usage on the 
impaired outcomes. We assessed mortality and recurrence in study subjects with a 
combination of at least three secondary preventive drugs and found that it was equally 
increased as in the main analyses which further supports that some other mechanism 
cause the impaired prognosis after ACS in patients with RA. There are obviously other 
types of secondary prevention, such as dietary recommendations, stress management 
and implementation of an adequate physical activity level, which we did not assess in 
this study.  
8.2.5 Heart failure in RA  
In Study IV, we reported an increased risk of HF regardless of the presence of IHD 
that could not be explained by CVDs or other conditions. There was no increased risk 
of HF prior to RA-onset, but it emerged rapidly after RA-onset and was associated 
with high inflammatory and disease activity. The early risk increase and the impact of 
high inflammatory activity was most pronounced for nonischemic HF. Since patients 
with RA more frequently develop IHD, the increased risk of ischemic HF is perhaps 
not surprising. However, the increased risk of nonischemic HF in our study is a novel 
finding. An association between inflammation and HF has been described as several 
studies have reported elevated inflammatory biomarkers in patients with HF. Whether 
there is a causal relationship between inflammation and HF is however not 
established. Our findings where the HF-risk developed first after RA-onset and was 
affected by high inflammatory activity, which was most pronounced for nonischemic 
HF do however support the hypothesis of a causal relationship between inflammation 
and HF onset or aggravation. There are several established effects of inflammatory 
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mediators on the myocardium. For example, various cytokines, such as TNF-α, which 
is also involved in the pathogenesis of RA, is associated with impaired myocardial 
contractility in septicaemia.170 Inflammation also leads to reduced cardiomyocyte 
contractility and induces hypertrophic and fibrotic response in the myocardium which 
could lead to development of HF.206  
Given the rapid increase of HF after RA-onset it is important to consider other 
potential risk factors, such as RA-related pharmacotherapies. In fact, we noted a 
strong association between usage of corticosteroids, which is common in the initial 
treatment of RA in Sweden, and the risk of nonischemic HF. Since it is the patients 
with high inflammatory and disease activity that are treated with corticosteroids, the 
observed association between corticosteroids and nonischemic HF might reflect 
inflammatory activity rather than the drug itself. However, the finding is a reason for 
concern. Treatment with the biologic drugs TNF-α antagonists in patients with HF has 
previously been a concern due to the elevated levels of TNF-α in individuals with HF. 
However, treatment with TNF-α antagonists in patients with HF, but without overt 
autoimmune disease, has shown no beneficial or harmful effect in severe HF.207 
Likewise, a study of RA-patients found no increased risk of HF among patients with 
TNF-α antagonists compared to traditional DMARDs.208 Furthermore, it has been 
hypothesized that TNF-α antagonists in RA can exert positive effects of cardiac 
function and disease biomarkers in HF.209, 210  
RF-positivity was associated with a greater risk of in particular ischemic HF in our 
study. Since RF-positivity is associated with high inflammatory and disease activity it 
is unclear whether RF per se is a risk factor or if the finding rather reflects the 
inflammation. RF correlates with the occurrence of ACPAs, which we did not have 
access to data on in this study. Citrullinated proteins in the myocardial interstitium, 
which is associated with interstitial fibrosis, have however been found to be increased 
in patients with RA.211 Moreover, a recent study found that citrullination can impair 
the contractility of cardiomyocytes by reducing the myofilament Ca2+ sensitivity.50 
Hence, inflammatory mediated signals affecting the myocardium could be involved in 
the pathogenesis of HF in RA.  
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9 CONCLUSIONS 
In this thesis, various clinical oriented research questions within the field of 
cardiovascular comorbidity in RA were explored. The results contribute to expanding 
the knowledge of CVD in RA, can be implemented in clinical practice, and may serve 
as point of departure for further investigations of the questions generated.  
The specific conclusions of the four sub-studies are:  
• Clinical markers of high inflammatory activity and high disease activity are 
associated with an increased risk of acute coronary syndrome in patients with incident 
RA (Study I).  
• Early treatment with DMARDs in incident RA is not associated with an increased risk 
of acute coronary syndrome (Study I).  
• Rheumatoid factor and/or ACPA positivity per se is not associated with an increased 
ACS-risk in incident RA, whereas high levels of ACPA seem to be associated with an 
increased risk (Study I).  
• Patients with RA suffer from, in terms of subtype, more severe acute coronary events, 
receive more invasive in-hospital interventions and suffer from more complications 
compared to non-RA patients (Study II).  
• Patients with RA suffer from impaired short- and long-term outcomes in terms of 
mortality and recurrent events, which cannot readily be explained by underlying 
comorbidity or type of ACS (Studies II and III).  
• When taking ACS subtypes into account, the usage of secondary preventive drugs is 
largely similar among patients with RA and ACS when compared to non-RA patients 
and ACS, and cannot therefore explain the poorer outcomes following ACS (Study 
III).  
• Patients with RA are at increased risk of HF both in the presence and absence of IHD 
(Study IV).  
• The risk of non-ischemic HF seems to develop rapid after RA-onset, whereas the risk 
of ischemic HF appears to develop more slowly (Study IV).  
• Clinical markers of high inflammatory activity are associated with the increased risk 
of both ischemic and non-ischemic HF, but are most pronounced for the increased 
risk of non-ischemic HF in incident RA (Study IV).  
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10 SUGGESTIONS FOR FUTURE RESEARCH 
The findings of each sub-study included in this thesis have raised several new 
questions, which will constitute the objectives of future studies, some of which are 
already planned and initiated, of CVD in RA.  
In Study I, the association between high inflammatory activity and disease activity 
and the risk of ACS in patients with incident RA was the main finding. Seropositivity 
for ACPAs was borderline significant associated with ACS, and there seemed to be an 
association between high ACPA-levels and ACS. Since ACPAs are a fairly novel group 
of autoantibodies, including several fine-specific subtypes, only a few studies have 
investigated their role in CV pathogenesis, which remains to be determined. Certain 
fine-specific ACPAs have, however, been associated with endothelial dysfunction and 
overall atherosclerotic burden, for example. Hence, investigating the potential 
association between fine-specific ACPAs and ACS in RA and in the general population 
and their potential usefulness as a clinical predictor of CV events would be of interest. 
Further exploration of the potential beneficial effect of other novel anti-inflammatory 
drugs could also confirm the results presented in the study. 
In Study II, the patients with established RA suffered from more severe ACS and also 
a substantially increased risk of dying after these events compared with general 
population comparators. The increased short-term mortality risk remained after 
adjusting for type of ACS, indicating a different aetiology of the impaired short-term 
prognosis. Since the histopathological features of atherosclerosis are affected by 
inflammation, potentially the extent and composition of coronary artery 
atherosclerosis differ in patients with RA compared to non-RA patients, and this could 
explain the more severe ACS and also impaired short-term prognosis. Comparing 
angiographic patterns between the RA patients compared to the non-RA patients with 
ACS included in the study could further elucidate the findings and hopefully shed 
some new light on the observed differences in clinical ACS characteristics and 
outcomes.  
In addition to the impaired short-term mortality, patients with RA are also at 
increased risk of long-term recurrence and mortality as presented in Study III. In the 
same study, usage of secondary preventive drugs was also assessed, but no apparent 
differences between RA and non-RA patients were identified and the usage of such 
drugs did not seem to explain the increased risk of developing additional acute 
coronary events or dying. Of course, these drugs are only one part of the secondary 
preventive strategies used following ACS. Other secondary preventive measurements 
include implementation of life-style-related implementations such as physical activity 
and dietary recommendations, which we did not have information on. We have 
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planned further investigation of such additional factors, which hopefully will provide 
further insights into the area.  
In Study IV we showed that the risk of HF is increased in RA independently of 
concomitant IHD, and that the risk increase is driven partly by inflammatory activity. 
Despite the association between inflammation and heart failure, few studies have 
addressed the association between RA and HF. We plan to pursue the study of HF in 
RA with characterizing the clinical presentation and assessing outcomes.  
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11 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
 
Epidemiologi  
Epidemiologi är ett forskningsfält där man kartlägger förekomsten av olika sjukdomar i 
en population samt studerar potentiella samband mellan olika exponeringar och 
sjukdomsförekomsten. I den här avhandlingen ingår 4 delstudier där vi använt 
registerbaserade källor, såsom nationella hälsoregister, och epidemiologisk metoder 
för att studera utvalda aspekter av sambandet mellan ledgångsreumatism och 
hjärtkärlsjukdom.  
Ledgångsreumatism 
Ledgångsreumatism, reumatoid artrit, är en kronisk reumatisk sjukdom som ungefär 
0.7% av Sveriges befolkning beräknas leva med. Sjukdomen drabbar oftare kvinnor 
jämfört med män och debuterar vanligen mellan 45 och 60 år. Ledgångsreumatism 
kännetecknas av svullna och ömma leder till följd av förhöjd inflammatorisk aktivitet 
lokalt i lederna. Den inflammatoriska aktiviteten är även förhöjd generellt i blodet, 
vilket ger upphov till andra symptom såsom trötthet. Trots mycket omfattande 
forskning så är det fortfarande inte helt klarlagt vad som orsakar ledgångsreumatism, 
men det verkar som att både miljö- och ärftliga faktorer spelar roll och även att de 
samverkar. Sjukdomsbilden och symptomen vid ledgångsreumatism varierar mycket 
från person till person. Vissa patienter med ledgångsreumatism bildar 
autoantikroppar som kan upptäckas med hjälp av blodprov. Autoantikroppar är 
antikroppar som ‘attackerar’ kroppens egna vävnader och de patienter som bildar 
dessa drabbas oftare av en svårare sjukdomsform. Behandlingen vid 
ledgångsreumatism har utvecklats och förbättrats avsevärt de senaste decennierna och 
syftar till att dämpa den inflammatoriska aktiviteten och därmed göra patienten 
besvärsfri.  
Ledgångsreumatism och hjärt- kärlsjukdom 
Det är sedan länge känt att patienter med ledgångsreumatism löper en ökad risk att 
drabbas av andra sjukdomar och även har en ökad dödlighet. Framför allt så löper 
patienter med ledgångsreumatism en ökad risk för att drabbas av och dö i hjärtkärl-
sjukdomar. I synnerhet har samsjukligheten med kranskärlssjukdom (kärlkramp eller 
hjärtinfarkt) blivit undersökt och risken att utveckla kranskärlssjukdom har visat sig 
vara påtagligt förhöjd vid ledgångsreumatism. Kranskärlssjukdom orsakas i sin tur av 
åderförkalkning, ateroskleros, av hjärtats kranskärl. Vid alltför utbredda förändringar 
eller om det plötsligt lossnar en bit av förändringarna (en så kallad propp) leder 
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åderförkalkningen till försämrat eller avstannat blodflöde vilket orsakar syrebrist i 
hjärtmuskulaturen. Detta yttrar sig antingen som kronisk kärlkramp eller som en akut 
hjärtinfarkt, som kan ha olika symptom och svårighetsgrad beroende på lokalisation 
av stoppet och hur utbredd syrebristen blir. Det har senaste tiden kunnat fastställas 
att inflammation är involverad i utvecklingen av åderförkalkning och även att 
inflammation bland annat påverkar hur stabila förändringarna blir, dvs. hur enkelt en 
propp kan lossna.  
Studie I – Riskfaktorer för akut kranskärlssjukdom vis ledgångsreumatism 
Det har visat sig att de traditionella riskfaktorerna för hjärtkärlsjukdom (rökning, 
fetma, diabetes, högt blodtryck och hypertoni) inte helt kan förklara riskökningen för 
hjärtkärlsjukdom bland patienter med ledgångsreumatism. Detta innebär att andra 
faktorer, åtminstone delvis, kan förklara utvecklingen av hjärtkärlsjukdom hos 
patienter med ledgångsreumatism. Då inflammatorisk aktivitet tycks vara en 
gemensam nämnare vid ledgångsreumatism och ateroskleros har olika markörer för 
inflammation utvärderats i flertalet studier som potentiella riskfaktorer för 
hjärtkärlsjukdom vid ledgångsreumatism och det har visat sig att hög inflammatorisk 
aktivitet är en riskfaktor för utvecklingen av hjärtkärlsjukdom både i vanliga 
befolkningen och hos patienter med ledgångsreumatism. Man har även funnit 
samband mellan olika ärftliga faktorer och autoantikroppar och risken att utveckla 
hjärtkärlsjukdom vid ledgångsreumatism.  
De flesta av tidigare studier som undersökt olika riskfaktorer för hjärtkärlsjukdom vid 
ledgångsreumatism är delvis baserade på äldre populationer, vilket gör det svårt att 
veta vilken deras effekt är på mer nutida patient-underlag som behandlas på ett annat 
sätt. Dels är studierna även baserade på alla olika typer av hjärtkärlsjukdom (som 
förutom kranskärlssjukdom även kan innefatta bland annat stroke och hjärtsvikt), 
vilket gör det svårt att veta vilken effekt de har på respektive sjukdom. I delstudie I 
undersökte vi därför olika potentiella riskfaktorer för akut kranskärlssjukdom 
vid ledgångsreumatism. Vi genomförde en så kallad fall-kontroll studie baserad på 
138 fall och 624 kontroller. Fallen utgjordes av patienter med ledgångsreumatism som 
utvecklat akut kranskärlssjukdom medan kontrollerna var patienter med 
ledgångsreumatism som inte utvecklat akut kranskärlssjukdom. Information om de 
olika riskfaktorerna insamlades från befintliga register-källor och medicinska journaler 
och jämfördes därefter mellan fall och kontroller. Det visade sig bland annat att 
hög inflammatorisk aktivitet och sjukdomsaktivitet redan under första året 
efter insjuknande i ledgångsreumatism var associerat med risk för akut 
kranskärlssjukdom. Likaså var höga nivåer av en utav autoantikropparna 
associerat med risk för akut kranskärlssjukdom. Våra resultat understryker 
vikten av att ledgångsreumatism behandlas framgångsrikt i tid för att 
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förhindra utvecklingen av andra sjukdomstillstånd såsom akut 
kranskärlssjukdom.  
Studie II - Allvarlighetsgrad och prognos efter akut kranskärlssjukdom  
Risken för patienter med ledgångsreumatism att drabbas av akut kranskärlssjukdom 
tycks således delvis drivas av andra faktorer än de traditionella riskfaktorerna. 
Eftersom inflammation påverkar både utbredningen och kompositionen av 
kärlförändringar är det möjligt att själva sjukdomsbilden vid akut kranskärlssjukdom 
skiljer sig åt hos patienter med ledgångsreumatism jämfört med patienter utan. Det 
finns även studier som påvisat att inflammatorisk aktivitet är förknippad med 
försämrad prognos efter akut kranskärlssjukdom. Om patienter med 
ledgångsreumatism faktiskt löper en ökad risk att drabbas av svårare 
kranskärlssjukdom så kan detta motivera en annan typ av klinisk handläggning och 
uppföljning. I studie II och III undersökte vi därför om akut kranskärlssjukdom 
skiljer sig åt avseende symptom, svårighetsgrad och behandling hos patienter 
med ledgångsreumatism jämfört med patienter utan ledgångsreumatism. 
Vidare så undersökte vi även om det fans någon skillnad i dödlighet och risken 
att drabbas av upprepade insjuknanden. Vi jämförde patienter med 
ledgångsreumatism som drabbats av akut kranskärlssjukdom med patienter utan 
ledgångsreumatism som drabbats av akut kranskärlssjukdom mellan 2007 och 2010. 
För dessa individer inhämtades data på sjukdomsbilden in från ett så kallat 
kvalitetsregister som innehåller information om hjärt-intensivvård. Individerna följdes 
även i det nationella patientregistret och dödsregistret för att identifiera de som dött 
eller utvecklat ytterligare episoder av akut kranskärlssjukdom. Våra resultat 
indikerar att patienter med ledgångsreumatism faktiskt drabbas av 
allvarligare akut kranskärlssjukdom jämfört med patienterna utan 
ledgångsreumatism.  Vidare så löpte patienterna med ledgångsreumatism i vår 
studie en ökad risk för att dö och utveckla upprepade insjuknanden i akut 
kranskärlssjukdom både på kort- och lång sikt. Dessa resultat uppmanar till 
att ledgångsreumatism bör uppmärksammas som en riskfaktor för att utveckla 
svåra typer av kranskärlssjukdom och försämrad prognos därefter.  
Studie III – Förebyggande läkemedelsbehandling efter akut kranskärlssjukdom 
Efter en akut kranskärlshändelse behandlas patienter med en kombination av 
läkemedel som förebygger ett återinsjuknande. En sämre användning av dessa 
läkemedel hos patienter med ledgångsreumatism skulle eventuellt kunna förklara den 
sämre långtidsprognosen som vi såg i studie III. I studie III så använde vi oss därför 
av läkemedelsregistret och tittade även på användningen av dessa läkemedel 
under ett år efter det akuta insjuknandet.  Vi kunde inte se några större 
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skillnader i användningen av förebyggande läkemedel mellan patienterna med 
ledgångsreumatism och de utan och kunde därmed inte heller förklara den 
försämrade prognosen med hjälp av detta.  
Studie IV – Hjärtsvikt vid ledgångsreumatism 
Hjärtsvikt är en annan typ av hjärtkärlsjukdom som innebär att hjärtats pumpförmåga 
är nedsatt till följd av påverkan på hjärtmuskulaturen. Högt blodtryck och 
kranskärlssjukdom är de vanligaste orsakerna till hjärtsvikt i västvärlden, men det 
finns många fler. Nyligen har man även funnit att det finns ett samband mellan 
inflammation och hjärtsvikt, men det är oklart om det är ett orsakssamband. Eftersom 
ledgångsreumatism är förknippat med kranskärlssjukdom är det inte förvånande att 
patienter med ledgångsreumatism även löper en ökad risk att drabbas av hjärtsvikt. 
Hjärtsvikt vid ledgångsreumatism har dock inte blivit undersökt i samma utsträckning 
som kranskärlssjukdom och det är oklart om ledgångsreumatism är förknippat med 
hjärtsvikt oberoende av kranskärlssjukdom. Målet med studie IV var att utvärdera 
den relativa risken för hjärtsvikt vid ledgångsreumatism. Vi utvärderade både 
risken för hjärtsvikt orsakad av kranskärlssjukdom och hjärtsvikt som inte 
orsakats av kranskärlssjukdom. Vidare så undersökte vi också hur bland annat 
inflammatorisk aktivitet påverkar risken att utveckla hjärtsvikt vid 
ledgångsreumatism.  Vi fann att patienterna med ledgångsreumatism i vår 
studie löpte en ökad risk att drabbas av bägge typerna av hjärtsvikt. 
Riskökningen inträffade tidigt efter insjuknande i ledgångsreumatism. Vidare 
så var hög inflammatorisk aktivitet och andra mått på hög sjukdomsaktivitet 
associerat med utvecklingen av hjärtsvikt och mer uttalad för hjärtsvikt som 
inte orsakats av kranskärlssjukdom. Resultaten indikerar att inflammationen 
vid ledgångsreumatism driver utvecklingen av hjärtsvikt inte enbart via 
kranskärlssjukdom utan även via andra mekanismer. Resultaten manar även 
till att tecken på hjärtsvikt bör uppmärksammas hos patienter som nyligen 
insjuknat i ledgångsreumatism.  
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